{
  "psilocybin": {
    "id": 1,
    "name": "Psilocybin",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 284.25,
    "therapeutic_area": "Psychedelic Therapy",
    "status": "Phase II Clinical Trials",
    "category": "psychedelics",
    "patent_status": "Patent-Free",
    "patent_number": "US8407129",
    "safety_score": 92,
    "efficacy_score": 74,
    "drug_likeness": 62,
    "confidence_score": 78,
    "discovery_date": "2025-02-22T11:51:09.823389",
    "ip_status": "Under Review",
    "receptor_binding": {
      "5-HT2A": 85,
      "5-HT2C": 86,
      "5-HT1A": 63,
      "D2": 37
    },
    "bioactivity_data": {
      "ic50_values": [
        44.685062071451156,
        678.0756775787987,
        454.4782531080479,
        474.3400138491968,
        270.434821508419
      ],
      "ki_values": [
        141.31877769294448,
        252.23985057460752
      ],
      "ec50_values": [
        580.2220300892664,
        1333.0520963963102
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2024.1617",
        "title": "Pharmacological characterization of psilocybin and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 90
      },
      {
        "doi": "10.1016/j.neuropharm.2020.2457",
        "title": "Pharmacological characterization of psilocybin and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 93
      },
      {
        "doi": "10.1124/jpet.2023.8384",
        "title": "Pharmacological characterization of psilocybin and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T11:51:09.823475"
  },
  "lsd": {
    "id": 2,
    "name": "Lsd",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 323.43,
    "therapeutic_area": "Psychedelic Research",
    "status": "Research Phase",
    "category": "psychedelics",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 89,
    "efficacy_score": 90,
    "drug_likeness": 70,
    "confidence_score": 76,
    "discovery_date": "2025-04-02T11:51:09.823483",
    "ip_status": "Under Review",
    "receptor_binding": {
      "5-HT2A": 87,
      "5-HT2C": 80,
      "5-HT1A": 59,
      "D2": 55
    },
    "bioactivity_data": {
      "ic50_values": [
        881.9202956678845,
        949.0241697483955,
        44.86951054902372,
        699.1043285662043,
        930.5093358778173
      ],
      "ki_values": [
        149.41671428285437
      ],
      "ec50_values": [
        1359.929495344857
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2024.2939",
        "title": "Pharmacological characterization of lsd and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1126/science.2020.7505",
        "title": "Pharmacological characterization of lsd and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 98
      },
      {
        "doi": "10.1126/science.2023.2401",
        "title": "Pharmacological characterization of lsd and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 90
      },
      {
        "doi": "10.1016/j.neuropharm.2021.4214",
        "title": "Pharmacological characterization of lsd and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 88
      },
      {
        "doi": "10.1016/j.neuropharm.2020.7144",
        "title": "Pharmacological characterization of lsd and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T11:51:09.823535"
  },
  "mdma": {
    "id": 3,
    "name": "Mdma",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 193.25,
    "therapeutic_area": "PTSD Therapy",
    "status": "Phase III Clinical Trials",
    "category": "psychedelics",
    "patent_status": "Patent Pending",
    "patent_number": "US6710293",
    "safety_score": 92,
    "efficacy_score": 69,
    "drug_likeness": 90,
    "confidence_score": 70,
    "discovery_date": "2025-01-13T11:51:09.823543",
    "ip_status": "Patented",
    "receptor_binding": {
      "5-HT2A": 93,
      "5-HT2C": 74,
      "5-HT1A": 80,
      "D2": 35
    },
    "bioactivity_data": {
      "ic50_values": [
        653.5822885142006,
        578.8283887460194,
        776.2602548324554,
        454.4315803841605
      ],
      "ki_values": [
        281.10577107802783,
        268.8366301406314
      ],
      "ec50_values": [
        55.96452490467745,
        8.954070186008272,
        1492.5121392928604
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2021.8032",
        "title": "Pharmacological characterization of mdma and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 93
      },
      {
        "doi": "10.1016/j.neuropharm.2023.4847",
        "title": "Pharmacological characterization of mdma and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 96
      },
      {
        "doi": "10.1021/jmedchem.2021.3997",
        "title": "Pharmacological characterization of mdma and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 88
      },
      {
        "doi": "10.1021/jmedchem.2022.6796",
        "title": "Pharmacological characterization of mdma and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T11:51:09.823586"
  },
  "dmt": {
    "id": 4,
    "name": "Dmt",
    "smiles": "CN(C)CCc1c[nH]c2ccccc12",
    "molecular_weight": 188.27,
    "therapeutic_area": "Psychedelic Research",
    "status": "Early Research",
    "category": "psychedelics",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 69,
    "efficacy_score": 75,
    "drug_likeness": 68,
    "confidence_score": 77,
    "discovery_date": "2025-08-14T11:51:09.823592",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "5-HT2A": 94,
      "5-HT2C": 72,
      "5-HT1A": 78,
      "D2": 20
    },
    "bioactivity_data": {
      "ic50_values": [
        802.3850911689188,
        686.7851572079473,
        133.84487130917833,
        96.04129682556777
      ],
      "ki_values": [
        100.37726507775695
      ],
      "ec50_values": [
        939.2336824352445,
        708.4601952137807
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2020.6788",
        "title": "Pharmacological characterization of dmt and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1021/jmedchem.2021.1409",
        "title": "Pharmacological characterization of dmt and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 93
      },
      {
        "doi": "10.1038/nature.2022.2961",
        "title": "Pharmacological characterization of dmt and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 89
      },
      {
        "doi": "10.1038/nature.2021.5606",
        "title": "Pharmacological characterization of dmt and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 93
      },
      {
        "doi": "10.1016/j.neuropharm.2022.6343",
        "title": "Pharmacological characterization of dmt and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.823638"
  },
  "mescaline": {
    "id": 5,
    "name": "Mescaline",
    "smiles": "COc1cc(CCN)cc(OC)c1OC",
    "molecular_weight": 211.26,
    "therapeutic_area": "Psychedelic Research",
    "status": "Research Phase",
    "category": "psychedelics",
    "patent_status": "Patent Pending",
    "patent_number": "US5091698",
    "safety_score": 86,
    "efficacy_score": 65,
    "drug_likeness": 62,
    "confidence_score": 71,
    "discovery_date": "2025-01-04T11:51:09.823645",
    "ip_status": "Patented",
    "receptor_binding": {
      "5-HT2A": 97,
      "5-HT2C": 72,
      "5-HT1A": 57,
      "D2": 31
    },
    "bioactivity_data": {
      "ic50_values": [
        849.0537353867222,
        100.33232200507754,
        874.6686660094067,
        526.9678421537176,
        684.5067688107614
      ],
      "ki_values": [
        36.33493830330414
      ],
      "ec50_values": [
        607.2359877046504
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound mescaline shows promising activity in Psychedelic Research applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2022.3671",
        "title": "Pharmacological characterization of mescaline and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 87
      },
      {
        "doi": "10.1038/nature.2024.7627",
        "title": "Pharmacological characterization of mescaline and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T11:51:09.823676"
  },
  "2c-b": {
    "id": 6,
    "name": "2C-B",
    "smiles": "COc1cc(CCN)cc(Br)c1OC",
    "molecular_weight": 260.12,
    "therapeutic_area": "Psychedelic Research",
    "status": "Research Chemical",
    "category": "psychedelics",
    "patent_status": "Patent Expired",
    "patent_number": "US5164924",
    "safety_score": 78,
    "efficacy_score": 67,
    "drug_likeness": 82,
    "confidence_score": 95,
    "discovery_date": "2025-02-17T11:51:09.823682",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "5-HT2A": 92,
      "5-HT2C": 80,
      "5-HT1A": 65,
      "D2": 38
    },
    "bioactivity_data": {
      "ic50_values": [
        301.7423482997466,
        476.79868932825065,
        734.347235923887,
        939.5240716090747,
        538.7356709307138
      ],
      "ki_values": [
        260.8275349588708,
        414.9151102585049,
        476.1900163426349
      ],
      "ec50_values": [
        1326.6116354926073,
        629.3603596673499
      ]
    },
    "research_notes": [
      "Compound 2c-b shows promising activity in Psychedelic Research applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2024.1866",
        "title": "Pharmacological characterization of 2c-b and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T11:51:09.823712"
  },
  "2c-i": {
    "id": 7,
    "name": "2C-I",
    "smiles": "COc1cc(CCN)cc(I)c1OC",
    "molecular_weight": 307.12,
    "therapeutic_area": "Psychedelic Research",
    "status": "Research Chemical",
    "category": "psychedelics",
    "patent_status": "Patent Pending",
    "patent_number": "US2462433",
    "safety_score": 67,
    "efficacy_score": 73,
    "drug_likeness": 62,
    "confidence_score": 79,
    "discovery_date": "2025-09-14T11:51:09.823718",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "5-HT2A": 88,
      "5-HT2C": 89,
      "5-HT1A": 71,
      "D2": 50
    },
    "bioactivity_data": {
      "ic50_values": [
        514.6196984150081,
        42.239637252623886
      ],
      "ki_values": [
        137.94351283088363
      ],
      "ec50_values": [
        159.00193265757392,
        1498.259543373457,
        819.2323649189985,
        1316.3918156868276
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound 2c-i shows promising activity in Psychedelic Research applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2020.7646",
        "title": "Pharmacological characterization of 2c-i and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 87
      },
      {
        "doi": "10.1021/jmedchem.2022.4355",
        "title": "Pharmacological characterization of 2c-i and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 87
      },
      {
        "doi": "10.1124/jpet.2021.4953",
        "title": "Pharmacological characterization of 2c-i and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 98
      },
      {
        "doi": "10.1124/jpet.2023.3162",
        "title": "Pharmacological characterization of 2c-i and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T11:51:09.823754"
  },
  "2c-e": {
    "id": 8,
    "name": "2C-E",
    "smiles": "CCOc1cc(CCN)cc(OCC)c1OC",
    "molecular_weight": 239.31,
    "therapeutic_area": "Psychedelic Research",
    "status": "Research Chemical",
    "category": "psychedelics",
    "patent_status": "Patent Pending",
    "patent_number": "US3084264",
    "safety_score": 63,
    "efficacy_score": 92,
    "drug_likeness": 71,
    "confidence_score": 91,
    "discovery_date": "2025-03-30T11:51:09.823759",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "5-HT2A": 80,
      "5-HT2C": 72,
      "5-HT1A": 72,
      "D2": 22
    },
    "bioactivity_data": {
      "ic50_values": [
        441.7327343576151
      ],
      "ki_values": [
        23.873517265663263
      ],
      "ec50_values": [
        1775.1333655231253
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound 2c-e shows promising activity in Psychedelic Research applications."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.5382",
        "title": "Pharmacological characterization of 2c-e and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 96
      },
      {
        "doi": "10.1124/jpet.2024.1273",
        "title": "Pharmacological characterization of 2c-e and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 97
      },
      {
        "doi": "10.1124/jpet.2021.5746",
        "title": "Pharmacological characterization of 2c-e and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 94
      },
      {
        "doi": "10.1126/science.2023.7317",
        "title": "Pharmacological characterization of 2c-e and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T11:51:09.823800"
  },
  "dob": {
    "id": 9,
    "name": "Dob",
    "smiles": "COc1cc(CCN)cc(Br)c1OC",
    "molecular_weight": 260.12,
    "therapeutic_area": "Psychedelic Research",
    "status": "Research Chemical",
    "category": "psychedelics",
    "patent_status": "Patented",
    "patent_number": "US5193497",
    "safety_score": 81,
    "efficacy_score": 73,
    "drug_likeness": 81,
    "confidence_score": 76,
    "discovery_date": "2025-01-18T11:51:09.823808",
    "ip_status": "Under Review",
    "receptor_binding": {
      "5-HT2A": 85,
      "5-HT2C": 82,
      "5-HT1A": 54,
      "D2": 44
    },
    "bioactivity_data": {
      "ic50_values": [
        567.2033305382182,
        980.161450870403,
        514.3569133901784,
        527.149229087796,
        920.7978043468546
      ],
      "ki_values": [
        34.03415627422406,
        73.70592703720116,
        49.804491087388456
      ],
      "ec50_values": [
        302.70399178288864,
        784.2650929834917,
        88.49580375329931
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2024.5310",
        "title": "Pharmacological characterization of dob and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 93
      },
      {
        "doi": "10.1038/nature.2020.1469",
        "title": "Pharmacological characterization of dob and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 88
      },
      {
        "doi": "10.1038/nature.2023.9495",
        "title": "Pharmacological characterization of dob and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 94
      },
      {
        "doi": "10.1016/j.neuropharm.2023.2749",
        "title": "Pharmacological characterization of dob and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T11:51:09.823843"
  },
  "doi": {
    "id": 10,
    "name": "Doi",
    "smiles": "COc1cc(CCN)cc(I)c1OC",
    "molecular_weight": 307.12,
    "therapeutic_area": "Psychedelic Research",
    "status": "Research Chemical",
    "category": "psychedelics",
    "patent_status": "Patent Expired",
    "patent_number": "US1246250",
    "safety_score": 60,
    "efficacy_score": 77,
    "drug_likeness": 83,
    "confidence_score": 77,
    "discovery_date": "2025-06-24T11:51:09.823848",
    "ip_status": "Under Review",
    "receptor_binding": {
      "5-HT2A": 91,
      "5-HT2C": 88,
      "5-HT1A": 54,
      "D2": 20
    },
    "bioactivity_data": {
      "ic50_values": [
        277.97340574331645,
        659.804824304974,
        789.8529391315374,
        332.2610542826521,
        272.8493631041849
      ],
      "ki_values": [
        278.80015001475346,
        368.5656308440779
      ],
      "ec50_values": [
        926.4609127752894,
        1675.453793345282,
        1960.5839002161565
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound doi shows promising activity in Psychedelic Research applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.6098",
        "title": "Pharmacological characterization of doi and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 97
      },
      {
        "doi": "10.1038/nature.2020.6840",
        "title": "Pharmacological characterization of doi and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 91
      },
      {
        "doi": "10.1038/nature.2021.6771",
        "title": "Pharmacological characterization of doi and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 92
      },
      {
        "doi": "10.1038/nature.2021.5332",
        "title": "Pharmacological characterization of doi and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 86
      },
      {
        "doi": "10.1021/jmedchem.2024.3832",
        "title": "Pharmacological characterization of doi and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T11:51:09.823886"
  },
  "ketamine": {
    "id": 11,
    "name": "Ketamine",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 237.73,
    "therapeutic_area": "Depression, Anesthesia",
    "status": "FDA Approved",
    "category": "ketamine_analogs",
    "patent_status": "Patent Pending",
    "patent_number": "US7241821",
    "safety_score": 86,
    "efficacy_score": 84,
    "drug_likeness": 66,
    "confidence_score": 91,
    "discovery_date": "2024-11-23T11:51:09.823892",
    "ip_status": "Patented",
    "receptor_binding": {
      "NMDA": 88,
      "AMPA": 45,
      "\u03c31": 50,
      "\u03bc-opioid": 25
    },
    "bioactivity_data": {
      "ic50_values": [
        241.95524436784356,
        40.93735167921448,
        288.11448465757104
      ],
      "ki_values": [
        39.07993254789992,
        487.3775502884395
      ],
      "ec50_values": [
        589.9076740419104
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2024.3878",
        "title": "Pharmacological characterization of ketamine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 92
      },
      {
        "doi": "10.1021/jmedchem.2021.5752",
        "title": "Pharmacological characterization of ketamine and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 98
      },
      {
        "doi": "10.1038/nature.2022.2828",
        "title": "Pharmacological characterization of ketamine and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 96
      },
      {
        "doi": "10.1016/j.neuropharm.2020.7578",
        "title": "Pharmacological characterization of ketamine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T11:51:09.823928"
  },
  "esketamine": {
    "id": 12,
    "name": "Esketamine",
    "smiles": "CN[C@]1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 237.73,
    "therapeutic_area": "Treatment-Resistant Depression",
    "status": "FDA Approved",
    "category": "ketamine_analogs",
    "patent_status": "Patent Expired",
    "patent_number": "US3064257",
    "safety_score": 88,
    "efficacy_score": 85,
    "drug_likeness": 78,
    "confidence_score": 90,
    "discovery_date": "2025-02-15T11:51:09.823934",
    "ip_status": "Under Review",
    "receptor_binding": {
      "NMDA": 91,
      "AMPA": 33,
      "\u03c31": 37,
      "\u03bc-opioid": 27
    },
    "bioactivity_data": {
      "ic50_values": [
        855.2961803570306,
        40.133945225261094,
        899.6402059780463,
        525.8972618275749,
        723.5737369296737
      ],
      "ki_values": [
        416.91597667013133
      ],
      "ec50_values": [
        1786.6459016457825
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound esketamine shows promising activity in Treatment-Resistant Depression applications."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2024.2165",
        "title": "Pharmacological characterization of esketamine and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 85
      },
      {
        "doi": "10.1126/science.2023.9969",
        "title": "Pharmacological characterization of esketamine and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 85
      },
      {
        "doi": "10.1126/science.2022.6464",
        "title": "Pharmacological characterization of esketamine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 91
      },
      {
        "doi": "10.1124/jpet.2024.7829",
        "title": "Pharmacological characterization of esketamine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 87
      },
      {
        "doi": "10.1126/science.2021.3136",
        "title": "Pharmacological characterization of esketamine and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T11:51:09.823974"
  },
  "arketamine": {
    "id": 13,
    "name": "Arketamine",
    "smiles": "CN[C@@]1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 237.73,
    "therapeutic_area": "Depression Research",
    "status": "Preclinical",
    "category": "ketamine_analogs",
    "patent_status": "Patent Expired",
    "patent_number": "US1566373",
    "safety_score": 92,
    "efficacy_score": 90,
    "drug_likeness": 66,
    "confidence_score": 79,
    "discovery_date": "2025-06-21T11:51:09.823979",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "NMDA": 90,
      "AMPA": 29,
      "\u03c31": 45,
      "\u03bc-opioid": 39
    },
    "bioactivity_data": {
      "ic50_values": [
        52.06507251860184,
        180.2104226236463,
        176.59494142949586
      ],
      "ki_values": [
        210.6247487055504
      ],
      "ec50_values": [
        403.57829255813783,
        1883.0287664947198,
        112.05417729081086,
        1254.208784666749
      ]
    },
    "research_notes": [
      "Compound arketamine shows promising activity in Depression Research applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.7482",
        "title": "Pharmacological characterization of arketamine and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 89
      },
      {
        "doi": "10.1016/j.neuropharm.2024.3366",
        "title": "Pharmacological characterization of arketamine and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824009"
  },
  "norketamine": {
    "id": 14,
    "name": "Norketamine",
    "smiles": "NC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 223.7,
    "therapeutic_area": "Ketamine Metabolite",
    "status": "Research",
    "category": "ketamine_analogs",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 60,
    "efficacy_score": 90,
    "drug_likeness": 89,
    "confidence_score": 96,
    "discovery_date": "2025-09-16T11:51:09.824015",
    "ip_status": "Patented",
    "receptor_binding": {
      "NMDA": 85,
      "AMPA": 27,
      "\u03c31": 35,
      "\u03bc-opioid": 31
    },
    "bioactivity_data": {
      "ic50_values": [
        242.5543855688197,
        359.6232994688688
      ],
      "ki_values": [
        491.31151324968926
      ],
      "ec50_values": [
        410.95144120577027
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound norketamine shows promising activity in Ketamine Metabolite applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2024.7039",
        "title": "Pharmacological characterization of norketamine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 90
      },
      {
        "doi": "10.1021/jmedchem.2020.3685",
        "title": "Pharmacological characterization of norketamine and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824169"
  },
  "hydroxynorketamine": {
    "id": 15,
    "name": "Hydroxynorketamine",
    "smiles": "NC1(CCCCC1=O)c2ccc(O)cc2Cl",
    "molecular_weight": 239.7,
    "therapeutic_area": "Depression Research",
    "status": "Research",
    "category": "ketamine_analogs",
    "patent_status": "Patent-Free",
    "patent_number": "US9258498",
    "safety_score": 92,
    "efficacy_score": 66,
    "drug_likeness": 78,
    "confidence_score": 73,
    "discovery_date": "2025-09-22T11:51:09.824176",
    "ip_status": "Under Review",
    "receptor_binding": {
      "NMDA": 94,
      "AMPA": 25,
      "\u03c31": 59,
      "\u03bc-opioid": 30
    },
    "bioactivity_data": {
      "ic50_values": [
        814.3713854100718
      ],
      "ki_values": [
        143.01228352918955
      ],
      "ec50_values": [
        1785.925626739037,
        880.4220493514671,
        1921.6096564177499
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2022.8450",
        "title": "Pharmacological characterization of hydroxynorketamine and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 92
      },
      {
        "doi": "10.1126/science.2020.6046",
        "title": "Pharmacological characterization of hydroxynorketamine and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824205"
  },
  "deschloroketamine": {
    "id": 16,
    "name": "Deschloroketamine",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2",
    "molecular_weight": 203.28,
    "therapeutic_area": "Research Chemical",
    "status": "Novel Research",
    "category": "ketamine_analogs",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 82,
    "efficacy_score": 69,
    "drug_likeness": 61,
    "confidence_score": 96,
    "discovery_date": "2025-07-09T11:51:09.824211",
    "ip_status": "Patented",
    "receptor_binding": {
      "NMDA": 94,
      "AMPA": 31,
      "\u03c31": 45,
      "\u03bc-opioid": 26
    },
    "bioactivity_data": {
      "ic50_values": [
        707.5450034147651,
        416.6971354046333,
        685.5202609533164
      ],
      "ki_values": [
        494.23454332298377,
        352.3549850912161
      ],
      "ec50_values": [
        90.5692797265593,
        1462.7247414506485
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound deschloroketamine shows promising activity in Research Chemical applications."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2022.1154",
        "title": "Pharmacological characterization of deschloroketamine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 95
      },
      {
        "doi": "10.1038/nature.2022.8590",
        "title": "Pharmacological characterization of deschloroketamine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1126/science.2024.8749",
        "title": "Pharmacological characterization of deschloroketamine and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 92
      },
      {
        "doi": "10.1126/science.2023.8323",
        "title": "Pharmacological characterization of deschloroketamine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1021/jmedchem.2020.3257",
        "title": "Pharmacological characterization of deschloroketamine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824255"
  },
  "2-fluorodeschloroketamine": {
    "id": 17,
    "name": "2-Fluorodeschloroketamine",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2F",
    "molecular_weight": 221.27,
    "therapeutic_area": "Research Chemical",
    "status": "Novel Research",
    "category": "ketamine_analogs",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 69,
    "efficacy_score": 72,
    "drug_likeness": 91,
    "confidence_score": 82,
    "discovery_date": "2025-06-28T11:51:09.824261",
    "ip_status": "Under Review",
    "receptor_binding": {
      "NMDA": 81,
      "AMPA": 22,
      "\u03c31": 39,
      "\u03bc-opioid": 27
    },
    "bioactivity_data": {
      "ic50_values": [
        909.6322143695929,
        988.8929358061066,
        506.2229699118085,
        721.1682453939652
      ],
      "ki_values": [
        33.865811042074895,
        331.72538418813383,
        80.08953220586912
      ],
      "ec50_values": [
        798.1716000513413,
        1942.669338668362
      ]
    },
    "research_notes": [
      "Compound 2-fluorodeschloroketamine shows promising activity in Research Chemical applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.6754",
        "title": "Pharmacological characterization of 2-fluorodeschloroketamine and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824287"
  },
  "methoxetamine": {
    "id": 18,
    "name": "Methoxetamine",
    "smiles": "CNC1(CCCC1)c2ccc(OC)cc2OC",
    "molecular_weight": 247.33,
    "therapeutic_area": "Research Chemical",
    "status": "Novel Research",
    "category": "ketamine_analogs",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 91,
    "efficacy_score": 67,
    "drug_likeness": 71,
    "confidence_score": 96,
    "discovery_date": "2024-12-11T11:51:09.824292",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "NMDA": 96,
      "AMPA": 40,
      "\u03c31": 36,
      "\u03bc-opioid": 16
    },
    "bioactivity_data": {
      "ic50_values": [
        938.1130247328899,
        807.6273558871745,
        275.0175582994508
      ],
      "ki_values": [
        139.36880279583292,
        49.9350949739387
      ],
      "ec50_values": [
        1460.6584434450833,
        1561.8226353823118,
        127.7518419824121,
        1417.5157527521158
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound methoxetamine shows promising activity in Research Chemical applications."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2020.1226",
        "title": "Pharmacological characterization of methoxetamine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 94
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824318"
  },
  "morphine": {
    "id": 19,
    "name": "Morphine",
    "smiles": "CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5",
    "molecular_weight": 285.34,
    "therapeutic_area": "Pain Management",
    "status": "FDA Approved",
    "category": "opioids",
    "patent_status": "Patent Expired",
    "patent_number": "US6725835",
    "safety_score": 76,
    "efficacy_score": 85,
    "drug_likeness": 75,
    "confidence_score": 71,
    "discovery_date": "2025-06-18T11:51:09.824324",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "\u03bc-opioid": 88,
      "\u03b4-opioid": 40,
      "\u03ba-opioid": 22,
      "NOP": 23
    },
    "bioactivity_data": {
      "ic50_values": [
        280.60268168203737,
        354.2189794005042,
        325.0250582718604,
        60.596335992864475,
        802.7406431699666
      ],
      "ki_values": [
        366.02901595890523,
        228.60877231551444
      ],
      "ec50_values": [
        184.69746363946587,
        693.4797734337012,
        1546.671496854052
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound morphine shows promising activity in Pain Management applications."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2022.4788",
        "title": "Pharmacological characterization of morphine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 86
      },
      {
        "doi": "10.1124/jpet.2024.8651",
        "title": "Pharmacological characterization of morphine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824352"
  },
  "oxycodone": {
    "id": 20,
    "name": "Oxycodone",
    "smiles": "COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341C(=O)OC",
    "molecular_weight": 315.36,
    "therapeutic_area": "Pain Management",
    "status": "FDA Approved",
    "category": "opioids",
    "patent_status": "Patent Pending",
    "patent_number": "US8071209",
    "safety_score": 60,
    "efficacy_score": 89,
    "drug_likeness": 62,
    "confidence_score": 93,
    "discovery_date": "2025-03-11T11:51:09.824358",
    "ip_status": "Under Review",
    "receptor_binding": {
      "\u03bc-opioid": 95,
      "\u03b4-opioid": 27,
      "\u03ba-opioid": 18,
      "NOP": 36
    },
    "bioactivity_data": {
      "ic50_values": [
        404.7907672875025,
        739.1847142724483
      ],
      "ki_values": [
        305.36924425198424,
        114.63095529867428
      ],
      "ec50_values": [
        1047.3419597539375,
        1246.6999908996231,
        1342.882798677335
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.6124",
        "title": "Pharmacological characterization of oxycodone and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824386"
  },
  "hydrocodone": {
    "id": 21,
    "name": "Hydrocodone",
    "smiles": "COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341C(=O)C",
    "molecular_weight": 299.36,
    "therapeutic_area": "Pain Management",
    "status": "FDA Approved",
    "category": "opioids",
    "patent_status": "Patent Expired",
    "patent_number": "US9367579",
    "safety_score": 93,
    "efficacy_score": 75,
    "drug_likeness": 83,
    "confidence_score": 72,
    "discovery_date": "2025-04-11T11:51:09.824392",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "\u03bc-opioid": 90,
      "\u03b4-opioid": 43,
      "\u03ba-opioid": 50,
      "NOP": 40
    },
    "bioactivity_data": {
      "ic50_values": [
        85.82760535363103,
        668.2301318485007,
        534.3328954669678,
        608.3954431375959
      ],
      "ki_values": [
        358.94379989835585
      ],
      "ec50_values": [
        431.4654777803058,
        1870.8510934358994,
        858.258318080628
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2024.9697",
        "title": "Pharmacological characterization of hydrocodone and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 92
      },
      {
        "doi": "10.1126/science.2020.3901",
        "title": "Pharmacological characterization of hydrocodone and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824420"
  },
  "fentanyl": {
    "id": 22,
    "name": "Fentanyl",
    "smiles": "CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1",
    "molecular_weight": 336.47,
    "therapeutic_area": "Severe Pain",
    "status": "FDA Approved",
    "category": "opioids",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 65,
    "efficacy_score": 96,
    "drug_likeness": 64,
    "confidence_score": 85,
    "discovery_date": "2025-03-03T11:51:09.824425",
    "ip_status": "Under Review",
    "receptor_binding": {
      "\u03bc-opioid": 87,
      "\u03b4-opioid": 57,
      "\u03ba-opioid": 19,
      "NOP": 27
    },
    "bioactivity_data": {
      "ic50_values": [
        907.2899717508984,
        388.23732059252416,
        940.1619693746233,
        239.72682261584208,
        914.0875713596788
      ],
      "ki_values": [
        110.80621782324492,
        117.59367605032716,
        103.94923413927151
      ],
      "ec50_values": [
        498.4652951953799,
        1950.6246934135363,
        1636.5961318850543,
        1680.6122870902875
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2024.8084",
        "title": "Pharmacological characterization of fentanyl and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 87
      },
      {
        "doi": "10.1021/jmedchem.2023.4747",
        "title": "Pharmacological characterization of fentanyl and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 97
      },
      {
        "doi": "10.1016/j.neuropharm.2021.9750",
        "title": "Pharmacological characterization of fentanyl and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 88
      },
      {
        "doi": "10.1126/science.2021.8471",
        "title": "Pharmacological characterization of fentanyl and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 90
      },
      {
        "doi": "10.1038/nature.2022.9713",
        "title": "Pharmacological characterization of fentanyl and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824463"
  },
  "tramadol": {
    "id": 23,
    "name": "Tramadol",
    "smiles": "COc1cccc(C2(O)CCCCC2CN(C)C)c1",
    "molecular_weight": 263.38,
    "therapeutic_area": "Moderate Pain",
    "status": "FDA Approved",
    "category": "opioids",
    "patent_status": "Patented",
    "patent_number": "US2776539",
    "safety_score": 60,
    "efficacy_score": 90,
    "drug_likeness": 87,
    "confidence_score": 94,
    "discovery_date": "2024-10-07T11:51:09.824469",
    "ip_status": "Patented",
    "receptor_binding": {
      "\u03bc-opioid": 89,
      "\u03b4-opioid": 53,
      "\u03ba-opioid": 45,
      "NOP": 29
    },
    "bioactivity_data": {
      "ic50_values": [
        55.809682202433166,
        613.1574277479567
      ],
      "ki_values": [
        372.7256094221308
      ],
      "ec50_values": [
        927.7428558939596,
        635.4739080116223
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound tramadol shows promising activity in Moderate Pain applications."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2021.8562",
        "title": "Pharmacological characterization of tramadol and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 85
      },
      {
        "doi": "10.1016/j.neuropharm.2023.2185",
        "title": "Pharmacological characterization of tramadol and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2023.4800",
        "title": "Pharmacological characterization of tramadol and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824499"
  },
  "buprenorphine": {
    "id": 24,
    "name": "Buprenorphine",
    "smiles": "COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(CC5CC5)CC[C@@]341C(C)(C)C",
    "molecular_weight": 467.64,
    "therapeutic_area": "Opioid Use Disorder",
    "status": "FDA Approved",
    "category": "opioids",
    "patent_status": "Patent Pending",
    "patent_number": "US1191672",
    "safety_score": 67,
    "efficacy_score": 97,
    "drug_likeness": 83,
    "confidence_score": 92,
    "discovery_date": "2025-03-22T11:51:09.824504",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "\u03bc-opioid": 98,
      "\u03b4-opioid": 54,
      "\u03ba-opioid": 26,
      "NOP": 29
    },
    "bioactivity_data": {
      "ic50_values": [
        838.2262719846584,
        746.7573839823779,
        989.0116291813493,
        27.368012564580685
      ],
      "ki_values": [
        54.18821254401326,
        53.842839440289595,
        349.04909378937043
      ],
      "ec50_values": [
        1798.4182781195425,
        825.9119147746446,
        306.84801885428203,
        1315.7150346241344
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.7474",
        "title": "Pharmacological characterization of buprenorphine and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 98
      },
      {
        "doi": "10.1016/j.neuropharm.2020.3519",
        "title": "Pharmacological characterization of buprenorphine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 90
      },
      {
        "doi": "10.1016/j.neuropharm.2021.1604",
        "title": "Pharmacological characterization of buprenorphine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 88
      },
      {
        "doi": "10.1016/j.neuropharm.2021.3128",
        "title": "Pharmacological characterization of buprenorphine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824541"
  },
  "codeine": {
    "id": 25,
    "name": "Codeine",
    "smiles": "COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341",
    "molecular_weight": 299.36,
    "therapeutic_area": "Mild Pain",
    "status": "FDA Approved",
    "category": "opioids",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 74,
    "efficacy_score": 85,
    "drug_likeness": 82,
    "confidence_score": 95,
    "discovery_date": "2024-12-15T11:51:09.824548",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "\u03bc-opioid": 93,
      "\u03b4-opioid": 28,
      "\u03ba-opioid": 35,
      "NOP": 37
    },
    "bioactivity_data": {
      "ic50_values": [
        307.0995597110201
      ],
      "ki_values": [
        17.643838732104346,
        395.84984320315925
      ],
      "ec50_values": [
        1508.1366680131405,
        267.1475154976102
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.6789",
        "title": "Pharmacological characterization of codeine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824572"
  },
  "methadone": {
    "id": 26,
    "name": "Methadone",
    "smiles": "CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c2ccccc2",
    "molecular_weight": 309.45,
    "therapeutic_area": "Opioid Maintenance",
    "status": "FDA Approved",
    "category": "opioids",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 83,
    "efficacy_score": 98,
    "drug_likeness": 77,
    "confidence_score": 80,
    "discovery_date": "2025-02-24T11:51:09.824577",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "\u03bc-opioid": 90,
      "\u03b4-opioid": 42,
      "\u03ba-opioid": 27,
      "NOP": 17
    },
    "bioactivity_data": {
      "ic50_values": [
        175.71808954586865,
        135.69089627622873,
        992.1791791073608,
        202.63648460895578,
        788.2379960560951
      ],
      "ki_values": [
        78.80987546375732,
        484.1884218308952,
        49.89957416407132
      ],
      "ec50_values": [
        67.1604576577093,
        879.6069654337047,
        1085.8293203111018
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound methadone shows promising activity in Opioid Maintenance applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2024.3050",
        "title": "Pharmacological characterization of methadone and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 86
      },
      {
        "doi": "10.1124/jpet.2023.3131",
        "title": "Pharmacological characterization of methadone and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824605"
  },
  "alprazolam": {
    "id": 27,
    "name": "Alprazolam",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 308.76,
    "therapeutic_area": "Anxiety, Panic",
    "status": "FDA Approved",
    "category": "benzodiazepines",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 68,
    "efficacy_score": 96,
    "drug_likeness": 89,
    "confidence_score": 88,
    "discovery_date": "2025-08-15T11:51:09.824610",
    "ip_status": "Patented",
    "receptor_binding": {
      "GABA-A": 88,
      "\u03b11": 85,
      "\u03b12": 82,
      "\u03b15": 63
    },
    "bioactivity_data": {
      "ic50_values": [
        330.8387377795035
      ],
      "ki_values": [
        176.7843583511318,
        19.402347367452702,
        151.78755326198322
      ],
      "ec50_values": [
        1239.4130677533265
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2020.3061",
        "title": "Pharmacological characterization of alprazolam and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 96
      },
      {
        "doi": "10.1021/jmedchem.2020.6816",
        "title": "Pharmacological characterization of alprazolam and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 97
      },
      {
        "doi": "10.1124/jpet.2022.5867",
        "title": "Pharmacological characterization of alprazolam and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824640"
  },
  "diazepam": {
    "id": 28,
    "name": "Diazepam",
    "smiles": "CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21",
    "molecular_weight": 284.74,
    "therapeutic_area": "Anxiety, Seizures",
    "status": "FDA Approved",
    "category": "benzodiazepines",
    "patent_status": "Patent Pending",
    "patent_number": "US2240279",
    "safety_score": 88,
    "efficacy_score": 95,
    "drug_likeness": 91,
    "confidence_score": 82,
    "discovery_date": "2025-06-12T11:51:09.824646",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "GABA-A": 95,
      "\u03b11": 84,
      "\u03b12": 78,
      "\u03b15": 77
    },
    "bioactivity_data": {
      "ic50_values": [
        511.9854917528797,
        627.3958389649789,
        876.7094688697712,
        588.1170645275026
      ],
      "ki_values": [
        316.6644656652179
      ],
      "ec50_values": [
        1567.1431092456723
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2020.1375",
        "title": "Pharmacological characterization of diazepam and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 87
      },
      {
        "doi": "10.1038/nature.2023.4672",
        "title": "Pharmacological characterization of diazepam and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824673"
  },
  "lorazepam": {
    "id": 29,
    "name": "Lorazepam",
    "smiles": "O=C1N=C(c2ccc(Cl)cc2Cl)c2cc(Cl)ccc2N1O",
    "molecular_weight": 321.16,
    "therapeutic_area": "Anxiety, Insomnia",
    "status": "FDA Approved",
    "category": "benzodiazepines",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 93,
    "efficacy_score": 97,
    "drug_likeness": 67,
    "confidence_score": 71,
    "discovery_date": "2024-10-29T11:51:09.824677",
    "ip_status": "Under Review",
    "receptor_binding": {
      "GABA-A": 94,
      "\u03b11": 84,
      "\u03b12": 84,
      "\u03b15": 61
    },
    "bioactivity_data": {
      "ic50_values": [
        821.2245517805225
      ],
      "ki_values": [
        358.55503133741416,
        491.56089391764675
      ],
      "ec50_values": [
        1222.7624419138197,
        1265.5018038422793,
        1444.0168261281465,
        652.9973995773353
      ]
    },
    "research_notes": [
      "Compound lorazepam shows promising activity in Anxiety, Insomnia applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2020.4557",
        "title": "Pharmacological characterization of lorazepam and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 97
      },
      {
        "doi": "10.1124/jpet.2022.6749",
        "title": "Pharmacological characterization of lorazepam and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824705"
  },
  "clonazepam": {
    "id": 30,
    "name": "Clonazepam",
    "smiles": "O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1",
    "molecular_weight": 315.71,
    "therapeutic_area": "Seizures, Panic",
    "status": "FDA Approved",
    "category": "benzodiazepines",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 85,
    "efficacy_score": 85,
    "drug_likeness": 58,
    "confidence_score": 94,
    "discovery_date": "2025-05-21T11:51:09.824710",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "GABA-A": 96,
      "\u03b11": 89,
      "\u03b12": 78,
      "\u03b15": 76
    },
    "bioactivity_data": {
      "ic50_values": [
        264.7173896379257,
        564.834415569961,
        682.9420904586349,
        888.2632673955331,
        358.8875090531012
      ],
      "ki_values": [
        465.0380413231003,
        483.6743759233007
      ],
      "ec50_values": [
        1557.4985672390865
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound clonazepam shows promising activity in Seizures, Panic applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.4554",
        "title": "Pharmacological characterization of clonazepam and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 88
      },
      {
        "doi": "10.1126/science.2021.3832",
        "title": "Pharmacological characterization of clonazepam and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 95
      },
      {
        "doi": "10.1126/science.2024.7538",
        "title": "Pharmacological characterization of clonazepam and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824741"
  },
  "midazolam": {
    "id": 31,
    "name": "Midazolam",
    "smiles": "Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2",
    "molecular_weight": 325.77,
    "therapeutic_area": "Anesthesia",
    "status": "FDA Approved",
    "category": "benzodiazepines",
    "patent_status": "Patent Expired",
    "patent_number": "US9421767",
    "safety_score": 82,
    "efficacy_score": 96,
    "drug_likeness": 77,
    "confidence_score": 85,
    "discovery_date": "2025-06-12T11:51:09.824747",
    "ip_status": "Under Review",
    "receptor_binding": {
      "GABA-A": 96,
      "\u03b11": 81,
      "\u03b12": 88,
      "\u03b15": 74
    },
    "bioactivity_data": {
      "ic50_values": [
        234.13979449872528,
        692.9130038789015,
        888.4928942918946,
        893.9273389960889
      ],
      "ki_values": [
        254.75941903630357
      ],
      "ec50_values": [
        410.16523915938717,
        1958.0378645620667,
        1823.1073162619953
      ]
    },
    "research_notes": [
      "Compound midazolam shows promising activity in Anesthesia applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2024.8375",
        "title": "Pharmacological characterization of midazolam and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 94
      },
      {
        "doi": "10.1038/nature.2021.4750",
        "title": "Pharmacological characterization of midazolam and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 90
      },
      {
        "doi": "10.1038/nature.2021.8663",
        "title": "Pharmacological characterization of midazolam and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 88
      },
      {
        "doi": "10.1016/j.neuropharm.2020.9112",
        "title": "Pharmacological characterization of midazolam and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824783"
  },
  "temazepam": {
    "id": 32,
    "name": "Temazepam",
    "smiles": "CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21",
    "molecular_weight": 300.74,
    "therapeutic_area": "Insomnia",
    "status": "FDA Approved",
    "category": "benzodiazepines",
    "patent_status": "Patent-Free",
    "patent_number": "US7794319",
    "safety_score": 88,
    "efficacy_score": 82,
    "drug_likeness": 91,
    "confidence_score": 90,
    "discovery_date": "2024-11-21T11:51:09.824788",
    "ip_status": "Under Review",
    "receptor_binding": {
      "GABA-A": 96,
      "\u03b11": 94,
      "\u03b12": 87,
      "\u03b15": 79
    },
    "bioactivity_data": {
      "ic50_values": [
        249.7973971379433,
        409.8161576988478
      ],
      "ki_values": [
        325.6562187680416
      ],
      "ec50_values": [
        1919.9838324492957,
        484.6438964347883,
        239.65694326877178,
        1574.887385909966
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2021.7551",
        "title": "Pharmacological characterization of temazepam and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 91
      },
      {
        "doi": "10.1021/jmedchem.2023.6511",
        "title": "Pharmacological characterization of temazepam and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 89
      },
      {
        "doi": "10.1021/jmedchem.2021.7152",
        "title": "Pharmacological characterization of temazepam and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824821"
  },
  "oxazepam": {
    "id": 33,
    "name": "Oxazepam",
    "smiles": "O=C1N=C(c2ccccc2)c2cc(Cl)ccc2N1O",
    "molecular_weight": 286.71,
    "therapeutic_area": "Anxiety",
    "status": "FDA Approved",
    "category": "benzodiazepines",
    "patent_status": "Patent Expired",
    "patent_number": "US3898373",
    "safety_score": 72,
    "efficacy_score": 76,
    "drug_likeness": 57,
    "confidence_score": 84,
    "discovery_date": "2025-09-01T11:51:09.824826",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "GABA-A": 93,
      "\u03b11": 82,
      "\u03b12": 80,
      "\u03b15": 67
    },
    "bioactivity_data": {
      "ic50_values": [
        138.80989165700623,
        238.99342577826786,
        59.50514317590163
      ],
      "ki_values": [
        365.69765289909094
      ],
      "ec50_values": [
        1518.704024684096
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound oxazepam shows promising activity in Anxiety applications.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.6333",
        "title": "Pharmacological characterization of oxazepam and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824851"
  },
  "etizolam": {
    "id": 34,
    "name": "Etizolam",
    "smiles": "CCc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 342.82,
    "therapeutic_area": "Anxiety Research",
    "status": "Research Chemical",
    "category": "benzodiazepines",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 85,
    "efficacy_score": 65,
    "drug_likeness": 85,
    "confidence_score": 74,
    "discovery_date": "2025-05-30T11:51:09.824856",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "GABA-A": 98,
      "\u03b11": 89,
      "\u03b12": 84,
      "\u03b15": 75
    },
    "bioactivity_data": {
      "ic50_values": [
        521.1928286802431
      ],
      "ki_values": [
        110.81731365510815,
        207.67203945967847
      ],
      "ec50_values": [
        131.64685944912372
      ]
    },
    "research_notes": [
      "Compound etizolam shows promising activity in Anxiety Research applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2022.7437",
        "title": "Pharmacological characterization of etizolam and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 87
      },
      {
        "doi": "10.1124/jpet.2021.3898",
        "title": "Pharmacological characterization of etizolam and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 96
      },
      {
        "doi": "10.1126/science.2022.6602",
        "title": "Pharmacological characterization of etizolam and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1038/nature.2024.8109",
        "title": "Pharmacological characterization of etizolam and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824888"
  },
  "sertraline": {
    "id": 35,
    "name": "Sertraline",
    "smiles": "CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21",
    "molecular_weight": 306.23,
    "therapeutic_area": "Depression, Anxiety",
    "status": "FDA Approved",
    "category": "antidepressants",
    "patent_status": "Patented",
    "patent_number": "US1934747",
    "safety_score": 76,
    "efficacy_score": 97,
    "drug_likeness": 86,
    "confidence_score": 70,
    "discovery_date": "2025-08-22T11:51:09.824896",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "SERT": 98,
      "NET": 15,
      "DAT": 12,
      "5-HT2C": 47
    },
    "bioactivity_data": {
      "ic50_values": [
        938.415801067844,
        103.85965098288234
      ],
      "ki_values": [
        32.12526224836398
      ],
      "ec50_values": [
        48.18764068629731,
        1397.4591704147251,
        1596.8080807080066
      ]
    },
    "research_notes": [
      "Compound sertraline shows promising activity in Depression, Anxiety applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2024.5869",
        "title": "Pharmacological characterization of sertraline and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 91
      },
      {
        "doi": "10.1038/nature.2022.7584",
        "title": "Pharmacological characterization of sertraline and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 87
      },
      {
        "doi": "10.1038/nature.2022.3987",
        "title": "Pharmacological characterization of sertraline and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 87
      },
      {
        "doi": "10.1021/jmedchem.2021.4327",
        "title": "Pharmacological characterization of sertraline and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 92
      },
      {
        "doi": "10.1016/j.neuropharm.2023.8082",
        "title": "Pharmacological characterization of sertraline and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824932"
  },
  "fluoxetine": {
    "id": 36,
    "name": "Fluoxetine",
    "smiles": "CNCCC(c1ccc(C(F)(F)F)cc1)Oc1ccccc1",
    "molecular_weight": 309.33,
    "therapeutic_area": "Depression, OCD",
    "status": "FDA Approved",
    "category": "antidepressants",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 77,
    "efficacy_score": 79,
    "drug_likeness": 68,
    "confidence_score": 86,
    "discovery_date": "2024-12-11T11:51:09.824937",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "SERT": 93,
      "NET": 47,
      "DAT": 15,
      "5-HT2C": 50
    },
    "bioactivity_data": {
      "ic50_values": [
        805.6512459460637,
        363.09857367251453
      ],
      "ki_values": [
        146.81300259728798
      ],
      "ec50_values": [
        478.5304623584694
      ]
    },
    "research_notes": [
      "Compound fluoxetine shows promising activity in Depression, OCD applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2021.3506",
        "title": "Pharmacological characterization of fluoxetine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T11:51:09.824964"
  },
  "paroxetine": {
    "id": 37,
    "name": "Paroxetine",
    "smiles": "Fc1ccc(C[C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1",
    "molecular_weight": 329.37,
    "therapeutic_area": "Depression, Anxiety",
    "status": "FDA Approved",
    "category": "antidepressants",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 86,
    "efficacy_score": 80,
    "drug_likeness": 95,
    "confidence_score": 96,
    "discovery_date": "2025-08-06T11:51:09.824969",
    "ip_status": "Patented",
    "receptor_binding": {
      "SERT": 98,
      "NET": 50,
      "DAT": 30,
      "5-HT2C": 30
    },
    "bioactivity_data": {
      "ic50_values": [
        158.98794516739378
      ],
      "ki_values": [
        317.6564318081631,
        183.5197306209448,
        225.03119850125276
      ],
      "ec50_values": [
        375.82655396971705,
        934.3865226479692
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound paroxetine shows promising activity in Depression, Anxiety applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2024.4985",
        "title": "Pharmacological characterization of paroxetine and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 92
      },
      {
        "doi": "10.1124/jpet.2023.3477",
        "title": "Pharmacological characterization of paroxetine and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 87
      },
      {
        "doi": "10.1021/jmedchem.2023.5806",
        "title": "Pharmacological characterization of paroxetine and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825000"
  },
  "citalopram": {
    "id": 38,
    "name": "Citalopram",
    "smiles": "N#CCC[C@H]1CCCC[C@H]1COc1ccc(F)cc1",
    "molecular_weight": 324.39,
    "therapeutic_area": "Depression",
    "status": "FDA Approved",
    "category": "antidepressants",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 62,
    "efficacy_score": 97,
    "drug_likeness": 63,
    "confidence_score": 89,
    "discovery_date": "2024-12-18T11:51:09.825004",
    "ip_status": "Patented",
    "receptor_binding": {
      "SERT": 87,
      "NET": 51,
      "DAT": 13,
      "5-HT2C": 47
    },
    "bioactivity_data": {
      "ic50_values": [
        844.3543094771842,
        764.6110081827379,
        158.8872218787955
      ],
      "ki_values": [
        440.15092853960533
      ],
      "ec50_values": [
        827.1157997231353
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound citalopram shows promising activity in Depression applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2022.5448",
        "title": "Pharmacological characterization of citalopram and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 96
      },
      {
        "doi": "10.1124/jpet.2022.5226",
        "title": "Pharmacological characterization of citalopram and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1016/j.neuropharm.2024.4978",
        "title": "Pharmacological characterization of citalopram and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1016/j.neuropharm.2021.2552",
        "title": "Pharmacological characterization of citalopram and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825036"
  },
  "escitalopram": {
    "id": 39,
    "name": "Escitalopram",
    "smiles": "N#CCC[C@H]1CCCC[C@H]1COc1ccc(F)cc1",
    "molecular_weight": 324.39,
    "therapeutic_area": "Depression, Anxiety",
    "status": "FDA Approved",
    "category": "antidepressants",
    "patent_status": "Patent-Free",
    "patent_number": "US6524328",
    "safety_score": 91,
    "efficacy_score": 75,
    "drug_likeness": 88,
    "confidence_score": 85,
    "discovery_date": "2024-11-24T11:51:09.825042",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "SERT": 82,
      "NET": 34,
      "DAT": 9,
      "5-HT2C": 44
    },
    "bioactivity_data": {
      "ic50_values": [
        211.65986002203115,
        757.8359090412681,
        673.9541669381696
      ],
      "ki_values": [
        58.545873508559595
      ],
      "ec50_values": [
        876.0964316639363
      ]
    },
    "research_notes": [
      "Compound escitalopram shows promising activity in Depression, Anxiety applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2020.8027",
        "title": "Pharmacological characterization of escitalopram and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 85
      },
      {
        "doi": "10.1016/j.neuropharm.2024.1339",
        "title": "Pharmacological characterization of escitalopram and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2020.6499",
        "title": "Pharmacological characterization of escitalopram and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825072"
  },
  "venlafaxine": {
    "id": 40,
    "name": "Venlafaxine",
    "smiles": "COc1ccc(C[C@H](CN(C)C)C2(O)CCCCC2)cc1",
    "molecular_weight": 277.4,
    "therapeutic_area": "Depression, Anxiety",
    "status": "FDA Approved",
    "category": "antidepressants",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 71,
    "efficacy_score": 84,
    "drug_likeness": 64,
    "confidence_score": 73,
    "discovery_date": "2025-05-28T11:51:09.825077",
    "ip_status": "Under Review",
    "receptor_binding": {
      "SERT": 97,
      "NET": 31,
      "DAT": 6,
      "5-HT2C": 45
    },
    "bioactivity_data": {
      "ic50_values": [
        392.7569534740287,
        338.02977498583954,
        130.25309115358755
      ],
      "ki_values": [
        406.64636988442595,
        478.1903453079273
      ],
      "ec50_values": [
        961.2493482840865,
        997.2762269785887
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2022.9055",
        "title": "Pharmacological characterization of venlafaxine and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1124/jpet.2020.4914",
        "title": "Pharmacological characterization of venlafaxine and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 94
      },
      {
        "doi": "10.1126/science.2021.2485",
        "title": "Pharmacological characterization of venlafaxine and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825115"
  },
  "duloxetine": {
    "id": 41,
    "name": "Duloxetine",
    "smiles": "CNCCC(c1cccs1)Oc1ccc2ccccc2c1",
    "molecular_weight": 297.42,
    "therapeutic_area": "Depression, Neuropathy",
    "status": "FDA Approved",
    "category": "antidepressants",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 60,
    "efficacy_score": 71,
    "drug_likeness": 94,
    "confidence_score": 78,
    "discovery_date": "2024-12-06T11:51:09.825120",
    "ip_status": "Under Review",
    "receptor_binding": {
      "SERT": 83,
      "NET": 34,
      "DAT": 12,
      "5-HT2C": 33
    },
    "bioactivity_data": {
      "ic50_values": [
        575.3980874000005,
        483.8009611651324,
        220.15216553254123,
        208.23470362091086
      ],
      "ki_values": [
        14.791220422839592
      ],
      "ec50_values": [
        1870.8720297466264,
        1195.2029415904744
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2020.6356",
        "title": "Pharmacological characterization of duloxetine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 86
      },
      {
        "doi": "10.1021/jmedchem.2024.7946",
        "title": "Pharmacological characterization of duloxetine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825148"
  },
  "bupropion": {
    "id": 42,
    "name": "Bupropion",
    "smiles": "CC(C)(C)NC[C@H](O)c1cccc(Cl)c1",
    "molecular_weight": 239.74,
    "therapeutic_area": "Depression, Smoking",
    "status": "FDA Approved",
    "category": "antidepressants",
    "patent_status": "Patent Expired",
    "patent_number": "US3292441",
    "safety_score": 93,
    "efficacy_score": 96,
    "drug_likeness": 86,
    "confidence_score": 96,
    "discovery_date": "2025-08-02T11:51:09.825153",
    "ip_status": "Under Review",
    "receptor_binding": {
      "SERT": 89,
      "NET": 37,
      "DAT": 19,
      "5-HT2C": 32
    },
    "bioactivity_data": {
      "ic50_values": [
        288.6904079263078,
        372.96255464694656,
        972.383192363485
      ],
      "ki_values": [
        493.85442558375354,
        10.332121499902057
      ],
      "ec50_values": [
        1858.6129242998584,
        980.1146348214974
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound bupropion shows promising activity in Depression, Smoking applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2021.9196",
        "title": "Pharmacological characterization of bupropion and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825178"
  },
  "aripiprazole": {
    "id": 43,
    "name": "Aripiprazole",
    "smiles": "O=C1CCc2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccc2N1",
    "molecular_weight": 448.39,
    "therapeutic_area": "Schizophrenia",
    "status": "FDA Approved",
    "category": "antipsychotics",
    "patent_status": "Patent-Free",
    "patent_number": "US9409618",
    "safety_score": 88,
    "efficacy_score": 80,
    "drug_likeness": 90,
    "confidence_score": 78,
    "discovery_date": "2025-02-12T11:51:09.825183",
    "ip_status": "Under Review",
    "receptor_binding": {
      "D2": 95,
      "D3": 75,
      "5-HT2A": 98,
      "5-HT1A": 71
    },
    "bioactivity_data": {
      "ic50_values": [
        387.7743058985112
      ],
      "ki_values": [
        203.8477156442427,
        314.76091027130906,
        370.8214207777307
      ],
      "ec50_values": [
        686.4402220507745
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound aripiprazole shows promising activity in Schizophrenia applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.5542",
        "title": "Pharmacological characterization of aripiprazole and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 87
      },
      {
        "doi": "10.1126/science.2022.9444",
        "title": "Pharmacological characterization of aripiprazole and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825210"
  },
  "risperidone": {
    "id": 44,
    "name": "Risperidone",
    "smiles": "CC1=C(CCN2CCC(c3noc4cc(F)ccc34)CC2)C(=O)N2CCCCC2=N1",
    "molecular_weight": 410.49,
    "therapeutic_area": "Schizophrenia",
    "status": "FDA Approved",
    "category": "antipsychotics",
    "patent_status": "Patent-Free",
    "patent_number": "US5878598",
    "safety_score": 92,
    "efficacy_score": 91,
    "drug_likeness": 80,
    "confidence_score": 75,
    "discovery_date": "2024-12-12T11:51:09.825216",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "D2": 90,
      "D3": 88,
      "5-HT2A": 89,
      "5-HT1A": 67
    },
    "bioactivity_data": {
      "ic50_values": [
        43.614324797956364,
        818.0100394104403,
        595.78283323713
      ],
      "ki_values": [
        465.54876892189463
      ],
      "ec50_values": [
        419.8259237462166,
        1763.193253995077,
        454.5325620987122
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.8621",
        "title": "Pharmacological characterization of risperidone and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 87
      },
      {
        "doi": "10.1016/j.neuropharm.2023.8892",
        "title": "Pharmacological characterization of risperidone and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 87
      },
      {
        "doi": "10.1124/jpet.2023.2094",
        "title": "Pharmacological characterization of risperidone and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 88
      },
      {
        "doi": "10.1038/nature.2022.9156",
        "title": "Pharmacological characterization of risperidone and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 92
      },
      {
        "doi": "10.1016/j.neuropharm.2024.5522",
        "title": "Pharmacological characterization of risperidone and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825260"
  },
  "quetiapine": {
    "id": 45,
    "name": "Quetiapine",
    "smiles": "OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1",
    "molecular_weight": 383.51,
    "therapeutic_area": "Schizophrenia, Bipolar",
    "status": "FDA Approved",
    "category": "antipsychotics",
    "patent_status": "Patent-Free",
    "patent_number": "US3131007",
    "safety_score": 63,
    "efficacy_score": 84,
    "drug_likeness": 81,
    "confidence_score": 98,
    "discovery_date": "2025-01-07T11:51:09.825269",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "D2": 89,
      "D3": 73,
      "5-HT2A": 95,
      "5-HT1A": 77
    },
    "bioactivity_data": {
      "ic50_values": [
        717.6402771995464,
        807.3254035979699,
        786.7357759413928
      ],
      "ki_values": [
        230.78857059878194,
        123.17955736848805,
        425.37976164218014
      ],
      "ec50_values": [
        1110.7564183897257,
        450.2955069088144
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound quetiapine shows promising activity in Schizophrenia, Bipolar applications."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2023.2949",
        "title": "Pharmacological characterization of quetiapine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 96
      },
      {
        "doi": "10.1038/nature.2021.9612",
        "title": "Pharmacological characterization of quetiapine and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 95
      },
      {
        "doi": "10.1126/science.2023.8027",
        "title": "Pharmacological characterization of quetiapine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 94
      },
      {
        "doi": "10.1126/science.2023.6330",
        "title": "Pharmacological characterization of quetiapine and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825304"
  },
  "olanzapine": {
    "id": 46,
    "name": "Olanzapine",
    "smiles": "CN1CCN(C2=Nc3cc(C)ccc3Nc3ccccc32)CC1",
    "molecular_weight": 312.44,
    "therapeutic_area": "Schizophrenia",
    "status": "FDA Approved",
    "category": "antipsychotics",
    "patent_status": "Patent Pending",
    "patent_number": "US8032575",
    "safety_score": 69,
    "efficacy_score": 98,
    "drug_likeness": 77,
    "confidence_score": 77,
    "discovery_date": "2025-04-19T11:51:09.825309",
    "ip_status": "Under Review",
    "receptor_binding": {
      "D2": 80,
      "D3": 83,
      "5-HT2A": 96,
      "5-HT1A": 71
    },
    "bioactivity_data": {
      "ic50_values": [
        281.79153966241313,
        120.02625731825574,
        751.558008200721,
        95.38525184138322
      ],
      "ki_values": [
        5.575393340398373
      ],
      "ec50_values": [
        920.746823988252
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2024.9823",
        "title": "Pharmacological characterization of olanzapine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 89
      },
      {
        "doi": "10.1124/jpet.2021.7763",
        "title": "Pharmacological characterization of olanzapine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 89
      },
      {
        "doi": "10.1016/j.neuropharm.2022.9880",
        "title": "Pharmacological characterization of olanzapine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 89
      },
      {
        "doi": "10.1126/science.2020.3789",
        "title": "Pharmacological characterization of olanzapine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 97
      },
      {
        "doi": "10.1126/science.2021.9237",
        "title": "Pharmacological characterization of olanzapine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825357"
  },
  "haloperidol": {
    "id": 47,
    "name": "Haloperidol",
    "smiles": "O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1",
    "molecular_weight": 375.87,
    "therapeutic_area": "Schizophrenia",
    "status": "FDA Approved",
    "category": "antipsychotics",
    "patent_status": "Patent Expired",
    "patent_number": "US2765778",
    "safety_score": 75,
    "efficacy_score": 87,
    "drug_likeness": 87,
    "confidence_score": 81,
    "discovery_date": "2025-06-19T11:51:09.825364",
    "ip_status": "Patented",
    "receptor_binding": {
      "D2": 88,
      "D3": 73,
      "5-HT2A": 93,
      "5-HT1A": 74
    },
    "bioactivity_data": {
      "ic50_values": [
        76.6929114959774,
        112.180567683101
      ],
      "ki_values": [
        34.43206691721983,
        281.5933551399541,
        170.31161012994372
      ],
      "ec50_values": [
        1086.0914127306894
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound haloperidol shows promising activity in Schizophrenia applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2021.4136",
        "title": "Pharmacological characterization of haloperidol and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825391"
  },
  "clozapine": {
    "id": 48,
    "name": "Clozapine",
    "smiles": "CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1",
    "molecular_weight": 326.83,
    "therapeutic_area": "Treatment-Resistant Schizophrenia",
    "status": "FDA Approved",
    "category": "antipsychotics",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 91,
    "efficacy_score": 68,
    "drug_likeness": 87,
    "confidence_score": 88,
    "discovery_date": "2025-07-18T11:51:09.825396",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "D2": 92,
      "D3": 82,
      "5-HT2A": 97,
      "5-HT1A": 81
    },
    "bioactivity_data": {
      "ic50_values": [
        280.20017221031634,
        847.7342517775311,
        798.0845185168612,
        364.7759181231986,
        473.35519857649416
      ],
      "ki_values": [
        275.5393776075133,
        151.97008248449876
      ],
      "ec50_values": [
        1752.1802526772792,
        1093.384634741202,
        742.4324416317648
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound clozapine shows promising activity in Treatment-Resistant Schizophrenia applications."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2022.5196",
        "title": "Pharmacological characterization of clozapine and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 93
      },
      {
        "doi": "10.1021/jmedchem.2023.3463",
        "title": "Pharmacological characterization of clozapine and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825424"
  },
  "amphetamine": {
    "id": 49,
    "name": "Amphetamine",
    "smiles": "CC(N)Cc1ccccc1",
    "molecular_weight": 135.21,
    "therapeutic_area": "ADHD, Narcolepsy",
    "status": "FDA Approved",
    "category": "stimulants",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 93,
    "efficacy_score": 86,
    "drug_likeness": 84,
    "confidence_score": 82,
    "discovery_date": "2025-03-01T11:51:09.825430",
    "ip_status": "Patented",
    "receptor_binding": {
      "DAT": 91,
      "NET": 92,
      "SERT": 55,
      "VMAT2": 68
    },
    "bioactivity_data": {
      "ic50_values": [
        527.2568409759032,
        461.36675158652804,
        774.9010748403748,
        30.063824802425735,
        117.11792825140279
      ],
      "ki_values": [
        112.72902056910073,
        303.6540845352943
      ],
      "ec50_values": [
        668.6426019581095,
        1014.4934993994216
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound amphetamine shows promising activity in ADHD, Narcolepsy applications."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.6760",
        "title": "Pharmacological characterization of amphetamine and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 92
      },
      {
        "doi": "10.1021/jmedchem.2021.4008",
        "title": "Pharmacological characterization of amphetamine and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 95
      },
      {
        "doi": "10.1016/j.neuropharm.2021.2983",
        "title": "Pharmacological characterization of amphetamine and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 87
      },
      {
        "doi": "10.1124/jpet.2022.9281",
        "title": "Pharmacological characterization of amphetamine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 88
      },
      {
        "doi": "10.1124/jpet.2022.6632",
        "title": "Pharmacological characterization of amphetamine and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825471"
  },
  "dextroamphetamine": {
    "id": 50,
    "name": "Dextroamphetamine",
    "smiles": "C[C@H](N)Cc1ccccc1",
    "molecular_weight": 135.21,
    "therapeutic_area": "ADHD",
    "status": "FDA Approved",
    "category": "stimulants",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 76,
    "efficacy_score": 86,
    "drug_likeness": 83,
    "confidence_score": 92,
    "discovery_date": "2025-03-14T11:51:09.825476",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "DAT": 89,
      "NET": 82,
      "SERT": 56,
      "VMAT2": 42
    },
    "bioactivity_data": {
      "ic50_values": [
        194.2063588344228,
        114.50546277009492
      ],
      "ki_values": [
        23.868439686676485,
        281.3704940973854
      ],
      "ec50_values": [
        694.9253806816502
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound dextroamphetamine shows promising activity in ADHD applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2021.7372",
        "title": "Pharmacological characterization of dextroamphetamine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 88
      },
      {
        "doi": "10.1038/nature.2021.4020",
        "title": "Pharmacological characterization of dextroamphetamine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 95
      },
      {
        "doi": "10.1124/jpet.2020.7655",
        "title": "Pharmacological characterization of dextroamphetamine and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825507"
  },
  "methylphenidate": {
    "id": 51,
    "name": "Methylphenidate",
    "smiles": "COC(=O)[C@H]1[C@@H]2CCN[C@@H](C2)C1c1ccccc1",
    "molecular_weight": 233.31,
    "therapeutic_area": "ADHD",
    "status": "FDA Approved",
    "category": "stimulants",
    "patent_status": "Patent Expired",
    "patent_number": "US3551414",
    "safety_score": 65,
    "efficacy_score": 96,
    "drug_likeness": 68,
    "confidence_score": 73,
    "discovery_date": "2024-11-22T11:51:09.825512",
    "ip_status": "Patented",
    "receptor_binding": {
      "DAT": 87,
      "NET": 77,
      "SERT": 38,
      "VMAT2": 51
    },
    "bioactivity_data": {
      "ic50_values": [
        86.53512065371164
      ],
      "ki_values": [
        437.8900508241911
      ],
      "ec50_values": [
        636.34933002272
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2024.3075",
        "title": "Pharmacological characterization of methylphenidate and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 94
      },
      {
        "doi": "10.1038/nature.2023.2614",
        "title": "Pharmacological characterization of methylphenidate and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1021/jmedchem.2023.6836",
        "title": "Pharmacological characterization of methylphenidate and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 87
      },
      {
        "doi": "10.1038/nature.2020.9238",
        "title": "Pharmacological characterization of methylphenidate and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825547"
  },
  "lisdexamfetamine": {
    "id": 52,
    "name": "Lisdexamfetamine",
    "smiles": "CCCCCCNC(=O)[C@H](N)Cc1ccccc1",
    "molecular_weight": 263.38,
    "therapeutic_area": "ADHD",
    "status": "FDA Approved",
    "category": "stimulants",
    "patent_status": "Patented",
    "patent_number": "US7211730",
    "safety_score": 78,
    "efficacy_score": 90,
    "drug_likeness": 55,
    "confidence_score": 71,
    "discovery_date": "2025-06-13T11:51:09.825553",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "DAT": 81,
      "NET": 77,
      "SERT": 32,
      "VMAT2": 48
    },
    "bioactivity_data": {
      "ic50_values": [
        783.0684173929789,
        84.96767826530619,
        34.48664166941109,
        31.68390739664813,
        551.1480769669757
      ],
      "ki_values": [
        92.73404845070777
      ],
      "ec50_values": [
        686.0660128708982
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound lisdexamfetamine shows promising activity in ADHD applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.6862",
        "title": "Pharmacological characterization of lisdexamfetamine and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1016/j.neuropharm.2023.3451",
        "title": "Pharmacological characterization of lisdexamfetamine and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 86
      },
      {
        "doi": "10.1124/jpet.2021.2884",
        "title": "Pharmacological characterization of lisdexamfetamine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825584"
  },
  "modafinil": {
    "id": 53,
    "name": "Modafinil",
    "smiles": "NC(=O)C[S@](=O)c1ccc(cc1)C(F)(F)F",
    "molecular_weight": 273.35,
    "therapeutic_area": "Narcolepsy",
    "status": "FDA Approved",
    "category": "stimulants",
    "patent_status": "Patent Expired",
    "patent_number": "US6319008",
    "safety_score": 68,
    "efficacy_score": 79,
    "drug_likeness": 76,
    "confidence_score": 82,
    "discovery_date": "2025-08-25T11:51:09.825589",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "DAT": 94,
      "NET": 95,
      "SERT": 70,
      "VMAT2": 46
    },
    "bioactivity_data": {
      "ic50_values": [
        179.8238175222311,
        296.91319756239324
      ],
      "ki_values": [
        248.41393422555385
      ],
      "ec50_values": [
        1381.0531719667383,
        577.9508026587922,
        977.7004979261823
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound modafinil shows promising activity in Narcolepsy applications."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2022.6466",
        "title": "Pharmacological characterization of modafinil and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825613"
  },
  "armodafinil": {
    "id": 54,
    "name": "Armodafinil",
    "smiles": "NC(=O)C[S@@](=O)c1ccc(cc1)C(F)(F)F",
    "molecular_weight": 273.35,
    "therapeutic_area": "Narcolepsy",
    "status": "FDA Approved",
    "category": "stimulants",
    "patent_status": "Patent-Free",
    "patent_number": "US9473766",
    "safety_score": 60,
    "efficacy_score": 67,
    "drug_likeness": 77,
    "confidence_score": 70,
    "discovery_date": "2025-08-27T11:51:09.825618",
    "ip_status": "Patented",
    "receptor_binding": {
      "DAT": 82,
      "NET": 90,
      "SERT": 49,
      "VMAT2": 64
    },
    "bioactivity_data": {
      "ic50_values": [
        923.620803273203,
        422.0006802406044,
        318.8708652928187
      ],
      "ki_values": [
        340.6456422767151
      ],
      "ec50_values": [
        803.4790086578414,
        1963.938823598462,
        1887.4878106117376
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound armodafinil shows promising activity in Narcolepsy applications."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.5865",
        "title": "Pharmacological characterization of armodafinil and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825645"
  },
  "cocaine": {
    "id": 55,
    "name": "Cocaine",
    "smiles": "COC(=O)[C@H]1[C@@H]2CC[C@@H](N2C)[C@H]1OC(=O)c1ccccc1",
    "molecular_weight": 303.36,
    "therapeutic_area": "Research Only",
    "status": "Controlled Substance",
    "category": "stimulants",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 84,
    "efficacy_score": 76,
    "drug_likeness": 95,
    "confidence_score": 90,
    "discovery_date": "2025-03-31T11:51:09.825653",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "DAT": 86,
      "NET": 88,
      "SERT": 57,
      "VMAT2": 41
    },
    "bioactivity_data": {
      "ic50_values": [
        211.0241314612808,
        565.9983379176576,
        259.49688852316456
      ],
      "ki_values": [
        419.475015542362,
        165.51987870482594,
        474.0433024891699
      ],
      "ec50_values": [
        193.1951696198823
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound cocaine shows promising activity in Research Only applications."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.4504",
        "title": "Pharmacological characterization of cocaine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825678"
  },
  "phenytoin": {
    "id": 56,
    "name": "Phenytoin",
    "smiles": "O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1",
    "molecular_weight": 252.27,
    "therapeutic_area": "Seizures",
    "status": "FDA Approved",
    "category": "anticonvulsants",
    "patent_status": "Patented",
    "patent_number": "US6624539",
    "safety_score": 75,
    "efficacy_score": 75,
    "drug_likeness": 60,
    "confidence_score": 84,
    "discovery_date": "2025-04-30T11:51:09.825683",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 89
    },
    "bioactivity_data": {
      "ic50_values": [
        35.06728074042719,
        208.37927943766502,
        811.3966052689836
      ],
      "ki_values": [
        340.75059440530123,
        385.2006879763384,
        478.65890225834187
      ],
      "ec50_values": [
        401.3151557262421,
        146.51754101540914,
        685.227185195483
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2021.7948",
        "title": "Pharmacological characterization of phenytoin and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825710"
  },
  "carbamazepine": {
    "id": 57,
    "name": "Carbamazepine",
    "smiles": "NC(=O)N1c2ccccc2C=Cc2ccccc21",
    "molecular_weight": 236.27,
    "therapeutic_area": "Seizures, Bipolar",
    "status": "FDA Approved",
    "category": "anticonvulsants",
    "patent_status": "Patent-Free",
    "patent_number": "US2936036",
    "safety_score": 84,
    "efficacy_score": 84,
    "drug_likeness": 72,
    "confidence_score": 81,
    "discovery_date": "2025-07-15T11:51:09.825716",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 73
    },
    "bioactivity_data": {
      "ic50_values": [
        652.5031714124875,
        654.8577170784791,
        592.3802476754205,
        385.17134224352066
      ],
      "ki_values": [
        47.560576983122736
      ],
      "ec50_values": [
        55.071058191343816
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2021.1679",
        "title": "Pharmacological characterization of carbamazepine and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 93
      },
      {
        "doi": "10.1126/science.2023.7376",
        "title": "Pharmacological characterization of carbamazepine and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 88
      },
      {
        "doi": "10.1124/jpet.2024.7866",
        "title": "Pharmacological characterization of carbamazepine and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825746"
  },
  "valproic_acid": {
    "id": 58,
    "name": "Valproic Acid",
    "smiles": "CCCC(CCC)C(=O)O",
    "molecular_weight": 144.21,
    "therapeutic_area": "Seizures, Bipolar",
    "status": "FDA Approved",
    "category": "anticonvulsants",
    "patent_status": "Patent Pending",
    "patent_number": "US4549541",
    "safety_score": 86,
    "efficacy_score": 80,
    "drug_likeness": 66,
    "confidence_score": 72,
    "discovery_date": "2025-05-17T11:51:09.825751",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 85
    },
    "bioactivity_data": {
      "ic50_values": [
        937.8696615534061,
        306.64263406913255,
        424.2180272585481
      ],
      "ki_values": [
        91.74095825179651,
        83.90990718076637
      ],
      "ec50_values": [
        1989.5892589964071,
        703.5343492257173
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2022.1597",
        "title": "Pharmacological characterization of valproic_acid and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 85
      },
      {
        "doi": "10.1124/jpet.2021.5275",
        "title": "Pharmacological characterization of valproic_acid and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 98
      },
      {
        "doi": "10.1016/j.neuropharm.2024.9721",
        "title": "Pharmacological characterization of valproic_acid and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825785"
  },
  "lamotrigine": {
    "id": 59,
    "name": "Lamotrigine",
    "smiles": "Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1",
    "molecular_weight": 256.09,
    "therapeutic_area": "Seizures, Bipolar",
    "status": "FDA Approved",
    "category": "anticonvulsants",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 62,
    "efficacy_score": 70,
    "drug_likeness": 67,
    "confidence_score": 79,
    "discovery_date": "2024-12-09T11:51:09.825790",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 81
    },
    "bioactivity_data": {
      "ic50_values": [
        538.368719709706,
        986.8774349386065,
        486.1770141249876
      ],
      "ki_values": [
        383.4073233164879
      ],
      "ec50_values": [
        599.692941036421,
        952.6333452064014
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound lamotrigine shows promising activity in Seizures, Bipolar applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2021.2323",
        "title": "Pharmacological characterization of lamotrigine and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 95
      },
      {
        "doi": "10.1016/j.neuropharm.2020.7201",
        "title": "Pharmacological characterization of lamotrigine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 94
      },
      {
        "doi": "10.1124/jpet.2020.3069",
        "title": "Pharmacological characterization of lamotrigine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825826"
  },
  "levetiracetam": {
    "id": 60,
    "name": "Levetiracetam",
    "smiles": "CC[C@H](C(=O)N1CCCC1=O)N",
    "molecular_weight": 170.21,
    "therapeutic_area": "Seizures",
    "status": "FDA Approved",
    "category": "anticonvulsants",
    "patent_status": "Patent Pending",
    "patent_number": "US9076508",
    "safety_score": 83,
    "efficacy_score": 71,
    "drug_likeness": 58,
    "confidence_score": 95,
    "discovery_date": "2025-05-16T11:51:09.825832",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 55
    },
    "bioactivity_data": {
      "ic50_values": [
        314.67296484971166,
        761.240037488348,
        431.3313770754193
      ],
      "ki_values": [
        323.529863493878,
        358.8086158794057,
        433.9663878701647
      ],
      "ec50_values": [
        856.8908929927484,
        1401.9401522056232,
        514.3504976962199
      ]
    },
    "research_notes": [
      "Compound levetiracetam shows promising activity in Seizures applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2024.9736",
        "title": "Pharmacological characterization of levetiracetam and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 95
      },
      {
        "doi": "10.1021/jmedchem.2022.4652",
        "title": "Pharmacological characterization of levetiracetam and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825861"
  },
  "gabapentin": {
    "id": 61,
    "name": "Gabapentin",
    "smiles": "NCC1(CC(=O)O)CCCCC1",
    "molecular_weight": 171.24,
    "therapeutic_area": "Seizures, Neuropathy",
    "status": "FDA Approved",
    "category": "anticonvulsants",
    "patent_status": "Patent Expired",
    "patent_number": "US8515073",
    "safety_score": 81,
    "efficacy_score": 73,
    "drug_likeness": 86,
    "confidence_score": 98,
    "discovery_date": "2025-03-08T11:51:09.825867",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 84
    },
    "bioactivity_data": {
      "ic50_values": [
        935.0988205675865,
        473.95971653627925,
        527.7119037187488
      ],
      "ki_values": [
        172.222899902192,
        313.2245947224915,
        88.18330795773161
      ],
      "ec50_values": [
        1762.4222508622047,
        1631.620410705664
      ]
    },
    "research_notes": [
      "Compound gabapentin shows promising activity in Seizures, Neuropathy applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2024.9359",
        "title": "Pharmacological characterization of gabapentin and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 91
      },
      {
        "doi": "10.1038/nature.2023.4780",
        "title": "Pharmacological characterization of gabapentin and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 89
      },
      {
        "doi": "10.1021/jmedchem.2023.6837",
        "title": "Pharmacological characterization of gabapentin and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825897"
  },
  "pregabalin": {
    "id": 62,
    "name": "Pregabalin",
    "smiles": "CC(C)C[C@H](CN)CC(=O)O",
    "molecular_weight": 159.23,
    "therapeutic_area": "Seizures, Neuropathy",
    "status": "FDA Approved",
    "category": "anticonvulsants",
    "patent_status": "Patented",
    "patent_number": "US6749755",
    "safety_score": 65,
    "efficacy_score": 91,
    "drug_likeness": 64,
    "confidence_score": 81,
    "discovery_date": "2025-07-13T11:51:09.825902",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 63
    },
    "bioactivity_data": {
      "ic50_values": [
        756.8541806153809,
        876.3896272961956,
        545.67328041829
      ],
      "ki_values": [
        314.42689708384484,
        254.48853753308362
      ],
      "ec50_values": [
        69.28692869869603,
        79.76983742987971,
        1251.795970826919,
        312.5945616293402
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2021.3616",
        "title": "Pharmacological characterization of pregabalin and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 87
      },
      {
        "doi": "10.1038/nature.2021.8815",
        "title": "Pharmacological characterization of pregabalin and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1016/j.neuropharm.2021.6009",
        "title": "Pharmacological characterization of pregabalin and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1126/science.2022.2578",
        "title": "Pharmacological characterization of pregabalin and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825935"
  },
  "buspirone": {
    "id": 63,
    "name": "Buspirone",
    "smiles": "O=C1CCN(CCCCN2CCN(c3ncccn3)CC2)CC1",
    "molecular_weight": 385.5,
    "therapeutic_area": "Anxiety",
    "status": "FDA Approved",
    "category": "anxiolytics",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 94,
    "efficacy_score": 84,
    "drug_likeness": 88,
    "confidence_score": 72,
    "discovery_date": "2025-01-06T11:51:09.825940",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 58
    },
    "bioactivity_data": {
      "ic50_values": [
        202.90951216150629,
        717.1280571000214
      ],
      "ki_values": [
        89.23814029494801,
        414.5484575928659,
        309.4938716153186
      ],
      "ec50_values": [
        966.2759890548374,
        1846.8735246917513
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2024.4320",
        "title": "Pharmacological characterization of buspirone and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 91
      },
      {
        "doi": "10.1016/j.neuropharm.2024.4011",
        "title": "Pharmacological characterization of buspirone and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 93
      },
      {
        "doi": "10.1021/jmedchem.2021.2297",
        "title": "Pharmacological characterization of buspirone and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T11:51:09.825969"
  },
  "hydroxyzine": {
    "id": 64,
    "name": "Hydroxyzine",
    "smiles": "OCCOCCN1CCN(C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)CC1",
    "molecular_weight": 374.9,
    "therapeutic_area": "Anxiety, Allergies",
    "status": "FDA Approved",
    "category": "anxiolytics",
    "patent_status": "Patent Pending",
    "patent_number": "US2107157",
    "safety_score": 95,
    "efficacy_score": 92,
    "drug_likeness": 86,
    "confidence_score": 79,
    "discovery_date": "2025-05-01T11:51:09.825975",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 52
    },
    "bioactivity_data": {
      "ic50_values": [
        929.0143721848892,
        118.80576299393896,
        860.5968217777345,
        740.4970494821104,
        960.4295964652302
      ],
      "ki_values": [
        417.6823564765073,
        351.84490694240435
      ],
      "ec50_values": [
        1509.8488528768717,
        766.2324028603442,
        570.641113683547,
        1141.491417174941
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.1498",
        "title": "Pharmacological characterization of hydroxyzine and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 98
      },
      {
        "doi": "10.1016/j.neuropharm.2022.2801",
        "title": "Pharmacological characterization of hydroxyzine and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826008"
  },
  "propranolol": {
    "id": 65,
    "name": "Propranolol",
    "smiles": "CC(C)NCC(O)COc1cccc2ccccc12",
    "molecular_weight": 259.34,
    "therapeutic_area": "Anxiety, Hypertension",
    "status": "FDA Approved",
    "category": "anxiolytics",
    "patent_status": "Patent-Free",
    "patent_number": "US8420523",
    "safety_score": 77,
    "efficacy_score": 97,
    "drug_likeness": 57,
    "confidence_score": 79,
    "discovery_date": "2024-09-29T11:51:09.826015",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 57
    },
    "bioactivity_data": {
      "ic50_values": [
        392.19224107503425,
        629.2738987979297,
        52.18593622114237,
        928.5978964325989,
        751.3976966164939
      ],
      "ki_values": [
        153.54225368063376,
        172.0984890533437,
        225.94463328774367
      ],
      "ec50_values": [
        419.893121080806,
        1077.0154117362306,
        465.7094212385096,
        505.9575901660384
      ]
    },
    "research_notes": [
      "Compound propranolol shows promising activity in Anxiety, Hypertension applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2021.3343",
        "title": "Pharmacological characterization of propranolol and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1016/j.neuropharm.2020.3646",
        "title": "Pharmacological characterization of propranolol and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 87
      },
      {
        "doi": "10.1124/jpet.2024.3373",
        "title": "Pharmacological characterization of propranolol and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826046"
  },
  "clonidine": {
    "id": 66,
    "name": "Clonidine",
    "smiles": "Nc1nc(Cl)c(Cl)cc1Nc1ccccc1Cl",
    "molecular_weight": 230.09,
    "therapeutic_area": "ADHD, Hypertension",
    "status": "FDA Approved",
    "category": "anxiolytics",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 65,
    "efficacy_score": 79,
    "drug_likeness": 69,
    "confidence_score": 72,
    "discovery_date": "2025-08-05T11:51:09.826051",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 68
    },
    "bioactivity_data": {
      "ic50_values": [
        255.15687527998884,
        162.9605376772177
      ],
      "ki_values": [
        332.97144040009994,
        481.64951581825363
      ],
      "ec50_values": [
        1175.998221473844,
        124.59318861054824
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2020.3445",
        "title": "Pharmacological characterization of clonidine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826075"
  },
  "opi_2025_x00": {
    "id": 67,
    "name": "Opi 2025 X00",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 241.68,
    "therapeutic_area": "Research Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US5443887",
    "safety_score": 88,
    "efficacy_score": 86,
    "drug_likeness": 80,
    "confidence_score": 79,
    "discovery_date": "2025-03-31T11:51:09.826081",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 66
    },
    "bioactivity_data": {
      "ic50_values": [
        86.32526623010838,
        516.7596543679299
      ],
      "ki_values": [
        147.07841806631905
      ],
      "ec50_values": [
        624.8501160416737
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2021.7565",
        "title": "Pharmacological characterization of opi_2025_x00 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826106"
  },
  "anti_2025_y01": {
    "id": 68,
    "name": "Anti 2025 Y01",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 239.31,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US1992942",
    "safety_score": 95,
    "efficacy_score": 73,
    "drug_likeness": 84,
    "confidence_score": 90,
    "discovery_date": "2025-07-12T11:51:09.826112",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 77
    },
    "bioactivity_data": {
      "ic50_values": [
        744.1538090381426
      ],
      "ki_values": [
        459.2297033106885
      ],
      "ec50_values": [
        1767.9271880114356,
        1065.4037701098503
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound anti_2025_y01 shows promising activity in Discovery Phase applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2021.2182",
        "title": "Pharmacological characterization of anti_2025_y01 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 93
      },
      {
        "doi": "10.1021/jmedchem.2023.5015",
        "title": "Pharmacological characterization of anti_2025_y01 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 93
      },
      {
        "doi": "10.1126/science.2022.7223",
        "title": "Pharmacological characterization of anti_2025_y01 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 97
      },
      {
        "doi": "10.1126/science.2020.8238",
        "title": "Pharmacological characterization of anti_2025_y01 and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 98
      },
      {
        "doi": "10.1021/jmedchem.2021.9475",
        "title": "Pharmacological characterization of anti_2025_y01 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826146"
  },
  "bzd_2025_z02": {
    "id": 69,
    "name": "Bzd 2025 Z02",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 220.16,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US9482253",
    "safety_score": 75,
    "efficacy_score": 74,
    "drug_likeness": 78,
    "confidence_score": 91,
    "discovery_date": "2024-11-09T11:51:09.826154",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 82
    },
    "bioactivity_data": {
      "ic50_values": [
        915.0036763460812,
        582.5015694233359,
        998.5867101025569,
        650.6551524808912,
        788.8550721644549
      ],
      "ki_values": [
        479.6517732713961,
        466.97276721437686,
        263.1173117802233
      ],
      "ec50_values": [
        65.73204434694696
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound bzd_2025_z02 shows promising activity in Preclinical applications."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2020.8785",
        "title": "Pharmacological characterization of bzd_2025_z02 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 93
      },
      {
        "doi": "10.1016/j.neuropharm.2020.5401",
        "title": "Pharmacological characterization of bzd_2025_z02 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 96
      },
      {
        "doi": "10.1016/j.neuropharm.2020.1244",
        "title": "Pharmacological characterization of bzd_2025_z02 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 86
      },
      {
        "doi": "10.1016/j.neuropharm.2020.2344",
        "title": "Pharmacological characterization of bzd_2025_z02 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826192"
  },
  "bzd_2024_b03": {
    "id": 70,
    "name": "Bzd 2024 B03",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 425.32,
    "therapeutic_area": "Discovery Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US1236190",
    "safety_score": 88,
    "efficacy_score": 77,
    "drug_likeness": 70,
    "confidence_score": 84,
    "discovery_date": "2024-10-02T11:51:09.826198",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 69
    },
    "bioactivity_data": {
      "ic50_values": [
        913.5353829004931,
        146.41192448354485,
        609.6325138200737,
        253.31293259119747,
        76.07224034357931
      ],
      "ki_values": [
        390.3029865524178,
        145.7010421846894
      ],
      "ec50_values": [
        1648.9893193712453,
        210.20964255611437
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2022.6864",
        "title": "Pharmacological characterization of bzd_2024_b03 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 92
      },
      {
        "doi": "10.1038/nature.2020.1150",
        "title": "Pharmacological characterization of bzd_2024_b03 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 95
      },
      {
        "doi": "10.1016/j.neuropharm.2020.4402",
        "title": "Pharmacological characterization of bzd_2024_b03 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 91
      },
      {
        "doi": "10.1126/science.2022.1035",
        "title": "Pharmacological characterization of bzd_2024_b03 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826248"
  },
  "mdma_2025_y04": {
    "id": 71,
    "name": "Mdma 2025 Y04",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 265.11,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 90,
    "efficacy_score": 84,
    "drug_likeness": 85,
    "confidence_score": 97,
    "discovery_date": "2025-09-13T11:51:09.826253",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 51
    },
    "bioactivity_data": {
      "ic50_values": [
        961.4822715037278,
        483.19238992603783,
        614.6777192983403,
        401.4349721119616,
        215.9781956901423
      ],
      "ki_values": [
        186.88724526603332,
        161.74782959980038
      ],
      "ec50_values": [
        1579.7317418049513
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound mdma_2025_y04 shows promising activity in Preclinical applications."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2021.6564",
        "title": "Pharmacological characterization of mdma_2025_y04 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1038/nature.2021.7057",
        "title": "Pharmacological characterization of mdma_2025_y04 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 90
      },
      {
        "doi": "10.1126/science.2024.6844",
        "title": "Pharmacological characterization of mdma_2025_y04 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826283"
  },
  "opi_2025_z05": {
    "id": 72,
    "name": "Opi 2025 Z05",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 383.68,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US8755133",
    "safety_score": 67,
    "efficacy_score": 86,
    "drug_likeness": 58,
    "confidence_score": 82,
    "discovery_date": "2025-01-17T11:51:09.826288",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 89
    },
    "bioactivity_data": {
      "ic50_values": [
        653.5089096594569,
        91.72923963030426,
        411.20558401253294,
        204.28386011085115,
        545.2646842901003
      ],
      "ki_values": [
        374.49859590758024,
        245.96436824785232
      ],
      "ec50_values": [
        321.7371608906525,
        730.4123420257795,
        1118.1474483153663,
        1118.1508067557377
      ]
    },
    "research_notes": [
      "Compound opi_2025_z05 shows promising activity in Novel Therapy applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2020.8510",
        "title": "Pharmacological characterization of opi_2025_z05 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 92
      },
      {
        "doi": "10.1016/j.neuropharm.2024.7539",
        "title": "Pharmacological characterization of opi_2025_z05 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 92
      },
      {
        "doi": "10.1038/nature.2024.3915",
        "title": "Pharmacological characterization of opi_2025_z05 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 85
      },
      {
        "doi": "10.1016/j.neuropharm.2020.6120",
        "title": "Pharmacological characterization of opi_2025_z05 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 88
      },
      {
        "doi": "10.1016/j.neuropharm.2022.9884",
        "title": "Pharmacological characterization of opi_2025_z05 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 94
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826326"
  },
  "psi_2025_z06": {
    "id": 73,
    "name": "Psi 2025 Z06",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 281.61,
    "therapeutic_area": "Novel Therapy",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US3290521",
    "safety_score": 70,
    "efficacy_score": 81,
    "drug_likeness": 64,
    "confidence_score": 87,
    "discovery_date": "2025-03-03T11:51:09.826335",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 51
    },
    "bioactivity_data": {
      "ic50_values": [
        866.1842716796153,
        657.7708936154105,
        892.4289900846327,
        357.1442128394708
      ],
      "ki_values": [
        57.13254708900576,
        302.3335347594872,
        82.93072357901158
      ],
      "ec50_values": [
        709.8506046373336
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound psi_2025_z06 shows promising activity in Novel Therapy applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2024.8691",
        "title": "Pharmacological characterization of psi_2025_z06 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 93
      },
      {
        "doi": "10.1126/science.2021.4043",
        "title": "Pharmacological characterization of psi_2025_z06 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 90
      },
      {
        "doi": "10.1021/jmedchem.2022.5363",
        "title": "Pharmacological characterization of psi_2025_z06 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 92
      },
      {
        "doi": "10.1021/jmedchem.2022.8722",
        "title": "Pharmacological characterization of psi_2025_z06 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 95
      },
      {
        "doi": "10.1126/science.2022.1488",
        "title": "Pharmacological characterization of psi_2025_z06 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826370"
  },
  "ket_2025_z07": {
    "id": 74,
    "name": "Ket 2025 Z07",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 476.05,
    "therapeutic_area": "Preclinical",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 78,
    "efficacy_score": 65,
    "drug_likeness": 67,
    "confidence_score": 92,
    "discovery_date": "2024-10-04T11:51:09.826375",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 84
    },
    "bioactivity_data": {
      "ic50_values": [
        729.8492413198583,
        777.1951397036779
      ],
      "ki_values": [
        207.3340344882964,
        396.6763678395396,
        441.80166105790533
      ],
      "ec50_values": [
        783.0668540497591,
        89.61790036392944
      ]
    },
    "research_notes": [
      "Compound ket_2025_z07 shows promising activity in Preclinical applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2020.4366",
        "title": "Pharmacological characterization of ket_2025_z07 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1124/jpet.2022.5813",
        "title": "Pharmacological characterization of ket_2025_z07 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826401"
  },
  "psi_2025_z08": {
    "id": 75,
    "name": "Psi 2025 Z08",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 358.96,
    "therapeutic_area": "Novel Therapy",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US6971252",
    "safety_score": 87,
    "efficacy_score": 82,
    "drug_likeness": 95,
    "confidence_score": 80,
    "discovery_date": "2025-02-14T11:51:09.826409",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 61
    },
    "bioactivity_data": {
      "ic50_values": [
        126.39003916619119,
        297.0969643073315,
        871.1829797569745
      ],
      "ki_values": [
        235.49131973664484,
        176.9437332399424,
        60.92247156760268
      ],
      "ec50_values": [
        178.76478779622747,
        152.8593390360621
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound psi_2025_z08 shows promising activity in Novel Therapy applications."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2024.4861",
        "title": "Pharmacological characterization of psi_2025_z08 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1038/nature.2020.3937",
        "title": "Pharmacological characterization of psi_2025_z08 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826438"
  },
  "mdma_2024_a09": {
    "id": 76,
    "name": "Mdma 2024 A09",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 434.81,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US5843472",
    "safety_score": 66,
    "efficacy_score": 92,
    "drug_likeness": 70,
    "confidence_score": 72,
    "discovery_date": "2025-08-23T11:51:09.826444",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 88
    },
    "bioactivity_data": {
      "ic50_values": [
        478.3056888438924,
        746.2392031780468
      ],
      "ki_values": [
        302.7476878169393
      ],
      "ec50_values": [
        606.4081686025693,
        1058.243819854019,
        247.21622944766966
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound mdma_2024_a09 shows promising activity in Preclinical applications."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2024.9006",
        "title": "Pharmacological characterization of mdma_2024_a09 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 98
      },
      {
        "doi": "10.1038/nature.2022.3817",
        "title": "Pharmacological characterization of mdma_2024_a09 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 96
      },
      {
        "doi": "10.1021/jmedchem.2023.7488",
        "title": "Pharmacological characterization of mdma_2024_a09 and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 87
      },
      {
        "doi": "10.1016/j.neuropharm.2020.1459",
        "title": "Pharmacological characterization of mdma_2024_a09 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826478"
  },
  "stim_2024_c10": {
    "id": 77,
    "name": "Stim 2024 C10",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 353.99,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US2367402",
    "safety_score": 74,
    "efficacy_score": 73,
    "drug_likeness": 71,
    "confidence_score": 97,
    "discovery_date": "2025-09-15T11:51:09.826484",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 86
    },
    "bioactivity_data": {
      "ic50_values": [
        441.3248393976695,
        512.5351873452042
      ],
      "ki_values": [
        140.10861715784512
      ],
      "ec50_values": [
        906.5473469698885
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.4369",
        "title": "Pharmacological characterization of stim_2024_c10 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 88
      },
      {
        "doi": "10.1038/nature.2024.5041",
        "title": "Pharmacological characterization of stim_2024_c10 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826514"
  },
  "lsd_2024_a11": {
    "id": 78,
    "name": "Lsd 2024 A11",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 251.41,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 80,
    "efficacy_score": 67,
    "drug_likeness": 77,
    "confidence_score": 85,
    "discovery_date": "2025-04-30T11:51:09.826518",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 69
    },
    "bioactivity_data": {
      "ic50_values": [
        393.9000444439359,
        996.0766634566417,
        274.04687287437827,
        206.61247411439874
      ],
      "ki_values": [
        380.8766335516855,
        123.70738098293992,
        200.0385120018276
      ],
      "ec50_values": [
        1981.3956720564822,
        4.805692132491652,
        1047.8755624351502
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound lsd_2024_a11 shows promising activity in Preclinical applications."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2020.2001",
        "title": "Pharmacological characterization of lsd_2024_a11 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826543"
  },
  "opi_2024_a12": {
    "id": 79,
    "name": "Opi 2024 A12",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 394.92,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US9588536",
    "safety_score": 74,
    "efficacy_score": 97,
    "drug_likeness": 77,
    "confidence_score": 75,
    "discovery_date": "2025-04-14T11:51:09.826550",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 65
    },
    "bioactivity_data": {
      "ic50_values": [
        738.1622487759735
      ],
      "ki_values": [
        204.26039118693495,
        332.9568611303825
      ],
      "ec50_values": [
        1560.9816164485435,
        275.25544787393466,
        1060.1971392014411,
        613.2876378977473
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound opi_2024_a12 shows promising activity in Research Phase applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2023.3847",
        "title": "Pharmacological characterization of opi_2024_a12 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 88
      },
      {
        "doi": "10.1021/jmedchem.2024.2280",
        "title": "Pharmacological characterization of opi_2024_a12 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 92
      },
      {
        "doi": "10.1038/nature.2020.4585",
        "title": "Pharmacological characterization of opi_2024_a12 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 96
      },
      {
        "doi": "10.1124/jpet.2024.7064",
        "title": "Pharmacological characterization of opi_2024_a12 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 89
      },
      {
        "doi": "10.1016/j.neuropharm.2024.8548",
        "title": "Pharmacological characterization of opi_2024_a12 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826587"
  },
  "mdma_2025_x13": {
    "id": 80,
    "name": "Mdma 2025 X13",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 214.43,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US3476750",
    "safety_score": 60,
    "efficacy_score": 74,
    "drug_likeness": 87,
    "confidence_score": 76,
    "discovery_date": "2025-07-29T11:51:09.826593",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 87
    },
    "bioactivity_data": {
      "ic50_values": [
        761.2964766311405
      ],
      "ki_values": [
        212.5425091378076,
        116.60685245280835
      ],
      "ec50_values": [
        26.28410013475772,
        300.6500563350117,
        462.85768332501107,
        747.6961214099401
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2023.5156",
        "title": "Pharmacological characterization of mdma_2025_x13 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 91
      },
      {
        "doi": "10.1038/nature.2024.3715",
        "title": "Pharmacological characterization of mdma_2025_x13 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 96
      },
      {
        "doi": "10.1124/jpet.2021.5093",
        "title": "Pharmacological characterization of mdma_2025_x13 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 85
      },
      {
        "doi": "10.1021/jmedchem.2020.7070",
        "title": "Pharmacological characterization of mdma_2025_x13 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826625"
  },
  "opi_2024_a14": {
    "id": 81,
    "name": "Opi 2024 A14",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 417.08,
    "therapeutic_area": "Discovery Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US3586534",
    "safety_score": 90,
    "efficacy_score": 87,
    "drug_likeness": 67,
    "confidence_score": 74,
    "discovery_date": "2025-04-29T11:51:09.826630",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 57
    },
    "bioactivity_data": {
      "ic50_values": [
        632.2880506453396,
        987.4496969262667,
        13.721382385175009,
        277.13594253944444,
        153.1783304332464
      ],
      "ki_values": [
        469.557817037275,
        466.7746937106619
      ],
      "ec50_values": [
        636.7078243517246
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.7157",
        "title": "Pharmacological characterization of opi_2024_a14 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 87
      },
      {
        "doi": "10.1124/jpet.2020.5971",
        "title": "Pharmacological characterization of opi_2024_a14 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2023.8310",
        "title": "Pharmacological characterization of opi_2024_a14 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826664"
  },
  "mdma_2024_a15": {
    "id": 82,
    "name": "Mdma 2024 A15",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 443.35,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 66,
    "efficacy_score": 77,
    "drug_likeness": 74,
    "confidence_score": 71,
    "discovery_date": "2024-10-24T11:51:09.826668",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 73
    },
    "bioactivity_data": {
      "ic50_values": [
        893.7660790178768,
        459.0309725017436,
        997.8641212169858,
        27.586099590321563
      ],
      "ki_values": [
        418.03932256804404,
        24.906847588892326
      ],
      "ec50_values": [
        708.0626320309938,
        613.201736639305
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2024.3276",
        "title": "Pharmacological characterization of mdma_2024_a15 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1126/science.2020.4775",
        "title": "Pharmacological characterization of mdma_2024_a15 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826698"
  },
  "bzd_2024_b16": {
    "id": 83,
    "name": "Bzd 2024 B16",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 305.25,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US5775427",
    "safety_score": 60,
    "efficacy_score": 97,
    "drug_likeness": 71,
    "confidence_score": 90,
    "discovery_date": "2024-11-12T11:51:09.826703",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 58
    },
    "bioactivity_data": {
      "ic50_values": [
        377.53055056939377,
        830.5325331069769,
        416.1072541579135,
        394.7681782651778,
        246.89182929783996
      ],
      "ki_values": [
        347.7948521616962,
        159.80425193248522,
        310.0627605911976
      ],
      "ec50_values": [
        1519.7269945809037,
        265.7212080229219
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound bzd_2024_b16 shows promising activity in Research Phase applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2021.7272",
        "title": "Pharmacological characterization of bzd_2024_b16 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1038/nature.2020.7661",
        "title": "Pharmacological characterization of bzd_2024_b16 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 97
      },
      {
        "doi": "10.1021/jmedchem.2024.8306",
        "title": "Pharmacological characterization of bzd_2024_b16 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 92
      },
      {
        "doi": "10.1016/j.neuropharm.2023.1175",
        "title": "Pharmacological characterization of bzd_2024_b16 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826765"
  },
  "ket_2025_z17": {
    "id": 84,
    "name": "Ket 2025 Z17",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 295.97,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 75,
    "efficacy_score": 79,
    "drug_likeness": 65,
    "confidence_score": 91,
    "discovery_date": "2025-09-18T11:51:09.826770",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 85
    },
    "bioactivity_data": {
      "ic50_values": [
        37.54916709709198,
        208.37441278363232,
        475.2009521766508
      ],
      "ki_values": [
        94.99445142222997,
        426.49061445939475,
        35.24976854134721
      ],
      "ec50_values": [
        1372.1990541480127
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2024.6999",
        "title": "Pharmacological characterization of ket_2025_z17 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826795"
  },
  "opi_2024_b18": {
    "id": 85,
    "name": "Opi 2024 B18",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 298.82,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US5393265",
    "safety_score": 81,
    "efficacy_score": 68,
    "drug_likeness": 82,
    "confidence_score": 95,
    "discovery_date": "2025-02-18T11:51:09.826805",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 88
    },
    "bioactivity_data": {
      "ic50_values": [
        593.2358243112826,
        730.0293171566658,
        863.268336850883,
        861.2145139101067,
        2.0201672213344697
      ],
      "ki_values": [
        271.32644600275825
      ],
      "ec50_values": [
        1703.800493155191,
        1064.4056011678574
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound opi_2024_b18 shows promising activity in Novel Therapy applications."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.8889",
        "title": "Pharmacological characterization of opi_2024_b18 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 86
      },
      {
        "doi": "10.1016/j.neuropharm.2020.5056",
        "title": "Pharmacological characterization of opi_2024_b18 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 94
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826833"
  },
  "stim_2025_x19": {
    "id": 86,
    "name": "Stim 2025 X19",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 492.33,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 72,
    "efficacy_score": 71,
    "drug_likeness": 59,
    "confidence_score": 72,
    "discovery_date": "2025-06-29T11:51:09.826838",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 76
    },
    "bioactivity_data": {
      "ic50_values": [
        933.6383176319365,
        764.9149230086525
      ],
      "ki_values": [
        239.96352263451567,
        235.49061959432098
      ],
      "ec50_values": [
        1597.6355464975818,
        1881.5040931183207,
        341.198178680352
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.3040",
        "title": "Pharmacological characterization of stim_2025_x19 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1038/nature.2020.6783",
        "title": "Pharmacological characterization of stim_2025_x19 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 96
      },
      {
        "doi": "10.1124/jpet.2023.6015",
        "title": "Pharmacological characterization of stim_2025_x19 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 91
      },
      {
        "doi": "10.1016/j.neuropharm.2023.4802",
        "title": "Pharmacological characterization of stim_2025_x19 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 98
      },
      {
        "doi": "10.1126/science.2023.1966",
        "title": "Pharmacological characterization of stim_2025_x19 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826876"
  },
  "ket_2024_a20": {
    "id": 87,
    "name": "Ket 2024 A20",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 275.05,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US9448186",
    "safety_score": 62,
    "efficacy_score": 93,
    "drug_likeness": 89,
    "confidence_score": 84,
    "discovery_date": "2025-05-08T11:51:09.826883",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 83
    },
    "bioactivity_data": {
      "ic50_values": [
        92.74609803432809,
        719.7826299296311,
        926.9447773796594
      ],
      "ki_values": [
        71.19108129424195,
        310.5012027559129
      ],
      "ec50_values": [
        1789.2351789811537,
        1261.668681122413,
        646.0136655912023
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound ket_2024_a20 shows promising activity in Discovery Phase applications.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.8446",
        "title": "Pharmacological characterization of ket_2024_a20 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826911"
  },
  "stim_2025_x21": {
    "id": 88,
    "name": "Stim 2025 X21",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 200.54,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US2984316",
    "safety_score": 76,
    "efficacy_score": 92,
    "drug_likeness": 66,
    "confidence_score": 85,
    "discovery_date": "2025-01-15T11:51:09.826916",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 61
    },
    "bioactivity_data": {
      "ic50_values": [
        526.8565725940035
      ],
      "ki_values": [
        108.45942321823271,
        420.5149577677623,
        177.65980178863913
      ],
      "ec50_values": [
        673.3225348617822,
        509.1054478736612,
        688.8488396228466,
        1547.2152764213495
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound stim_2025_x21 shows promising activity in Preclinical applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2022.3101",
        "title": "Pharmacological characterization of stim_2025_x21 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 95
      },
      {
        "doi": "10.1126/science.2024.8292",
        "title": "Pharmacological characterization of stim_2025_x21 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 88
      },
      {
        "doi": "10.1126/science.2023.6112",
        "title": "Pharmacological characterization of stim_2025_x21 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826946"
  },
  "opi_2025_z22": {
    "id": 89,
    "name": "Opi 2025 Z22",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 209.47,
    "therapeutic_area": "Research Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US7930582",
    "safety_score": 61,
    "efficacy_score": 82,
    "drug_likeness": 85,
    "confidence_score": 72,
    "discovery_date": "2024-11-16T11:51:09.826951",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 80
    },
    "bioactivity_data": {
      "ic50_values": [
        807.9417771230628,
        423.7361680045534,
        144.00034746281912,
        708.1409298301506,
        850.8856683776767
      ],
      "ki_values": [
        461.1743966346093,
        30.36636437875712
      ],
      "ec50_values": [
        1580.7790754270145,
        1470.53282613269,
        232.39416090108347,
        3.4262752031518424
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound opi_2025_z22 shows promising activity in Research Phase applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2024.6802",
        "title": "Pharmacological characterization of opi_2025_z22 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2023.9374",
        "title": "Pharmacological characterization of opi_2025_z22 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 94
      }
    ],
    "last_updated": "2025-09-24T11:51:09.826981"
  },
  "psi_2025_x23": {
    "id": 90,
    "name": "Psi 2025 X23",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 422.13,
    "therapeutic_area": "Discovery Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US9078242",
    "safety_score": 78,
    "efficacy_score": 96,
    "drug_likeness": 71,
    "confidence_score": 96,
    "discovery_date": "2025-07-29T11:51:09.826987",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 50
    },
    "bioactivity_data": {
      "ic50_values": [
        115.46851016751813
      ],
      "ki_values": [
        483.2165570800351
      ],
      "ec50_values": [
        1509.429732377812
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.3766",
        "title": "Pharmacological characterization of psi_2025_x23 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 86
      },
      {
        "doi": "10.1016/j.neuropharm.2023.3494",
        "title": "Pharmacological characterization of psi_2025_x23 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827013"
  },
  "anti_2025_x24": {
    "id": 91,
    "name": "Anti 2025 X24",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 379.69,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US4372006",
    "safety_score": 62,
    "efficacy_score": 70,
    "drug_likeness": 62,
    "confidence_score": 80,
    "discovery_date": "2025-05-09T11:51:09.827018",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 83
    },
    "bioactivity_data": {
      "ic50_values": [
        337.63320184935753,
        494.50531728001005,
        960.9162728945483,
        435.7117331302179,
        497.50397046106104
      ],
      "ki_values": [
        297.9245367377455,
        64.04621688193231
      ],
      "ec50_values": [
        1426.4541027888306,
        1452.1216953545843,
        1090.4173809890758
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2020.6763",
        "title": "Pharmacological characterization of anti_2025_x24 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 86
      },
      {
        "doi": "10.1021/jmedchem.2020.7551",
        "title": "Pharmacological characterization of anti_2025_x24 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 92
      },
      {
        "doi": "10.1126/science.2023.3609",
        "title": "Pharmacological characterization of anti_2025_x24 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 97
      },
      {
        "doi": "10.1126/science.2021.8618",
        "title": "Pharmacological characterization of anti_2025_x24 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827055"
  },
  "opi_2024_c25": {
    "id": 92,
    "name": "Opi 2024 C25",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 317.29,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US1603731",
    "safety_score": 87,
    "efficacy_score": 90,
    "drug_likeness": 87,
    "confidence_score": 84,
    "discovery_date": "2025-07-14T11:51:09.827060",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 60
    },
    "bioactivity_data": {
      "ic50_values": [
        932.3331807773375,
        122.21934770995455,
        326.9630303770235,
        899.7757336712957,
        990.5462871133736
      ],
      "ki_values": [
        431.3236332528155,
        364.29053832213754,
        356.86529243190085
      ],
      "ec50_values": [
        852.878027511964
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound opi_2024_c25 shows promising activity in Preclinical applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2024.5160",
        "title": "Pharmacological characterization of opi_2024_c25 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 86
      },
      {
        "doi": "10.1126/science.2021.2262",
        "title": "Pharmacological characterization of opi_2024_c25 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 95
      },
      {
        "doi": "10.1038/nature.2020.2785",
        "title": "Pharmacological characterization of opi_2024_c25 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1016/j.neuropharm.2023.7661",
        "title": "Pharmacological characterization of opi_2024_c25 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827094"
  },
  "stim_2024_b26": {
    "id": 93,
    "name": "Stim 2024 B26",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 421.66,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 83,
    "efficacy_score": 83,
    "drug_likeness": 92,
    "confidence_score": 88,
    "discovery_date": "2024-12-03T11:51:09.827099",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 86
    },
    "bioactivity_data": {
      "ic50_values": [
        704.0282534496556,
        775.5769738409139
      ],
      "ki_values": [
        415.1072437382405,
        285.36694516870534
      ],
      "ec50_values": [
        1644.1278173536898,
        1140.9619979942604
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2022.5807",
        "title": "Pharmacological characterization of stim_2024_b26 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 92
      },
      {
        "doi": "10.1126/science.2022.2418",
        "title": "Pharmacological characterization of stim_2024_b26 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827128"
  },
  "mdma_2024_a27": {
    "id": 94,
    "name": "Mdma 2024 A27",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 326.32,
    "therapeutic_area": "Research Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 74,
    "efficacy_score": 89,
    "drug_likeness": 61,
    "confidence_score": 70,
    "discovery_date": "2025-04-13T11:51:09.827133",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 56
    },
    "bioactivity_data": {
      "ic50_values": [
        168.02436512830639,
        149.62984708648918
      ],
      "ki_values": [
        388.4233947073703,
        432.5515335772953,
        292.9924802915756
      ],
      "ec50_values": [
        1531.4480011279377,
        486.5296428886132
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.1303",
        "title": "Pharmacological characterization of mdma_2024_a27 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827157"
  },
  "ket_2025_y28": {
    "id": 95,
    "name": "Ket 2025 Y28",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 183.45,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US4645121",
    "safety_score": 72,
    "efficacy_score": 68,
    "drug_likeness": 94,
    "confidence_score": 97,
    "discovery_date": "2024-11-05T11:51:09.827165",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 69
    },
    "bioactivity_data": {
      "ic50_values": [
        876.5911564367359,
        78.01359529103752,
        283.5309128344626,
        340.37333405250195,
        166.6296906356354
      ],
      "ki_values": [
        209.85881160414044
      ],
      "ec50_values": [
        1614.6160066653113,
        1063.3414309172247,
        613.9081124422903,
        225.2694398932797
      ]
    },
    "research_notes": [
      "Compound ket_2025_y28 shows promising activity in Novel Therapy applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2023.2291",
        "title": "Pharmacological characterization of ket_2025_y28 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 86
      },
      {
        "doi": "10.1126/science.2020.8796",
        "title": "Pharmacological characterization of ket_2025_y28 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 87
      },
      {
        "doi": "10.1038/nature.2023.2486",
        "title": "Pharmacological characterization of ket_2025_y28 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 97
      },
      {
        "doi": "10.1021/jmedchem.2020.4471",
        "title": "Pharmacological characterization of ket_2025_y28 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 87
      },
      {
        "doi": "10.1126/science.2022.7683",
        "title": "Pharmacological characterization of ket_2025_y28 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827206"
  },
  "mdma_2025_x29": {
    "id": 96,
    "name": "Mdma 2025 X29",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 166.59,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US5946020",
    "safety_score": 87,
    "efficacy_score": 67,
    "drug_likeness": 58,
    "confidence_score": 71,
    "discovery_date": "2025-05-15T11:51:09.827212",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 82
    },
    "bioactivity_data": {
      "ic50_values": [
        373.6625964179803,
        795.3282826316394,
        583.4856830613991
      ],
      "ki_values": [
        455.3631652793472,
        284.05139039376587,
        61.90391253490104
      ],
      "ec50_values": [
        1841.85559173064
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2020.5866",
        "title": "Pharmacological characterization of mdma_2025_x29 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 94
      },
      {
        "doi": "10.1124/jpet.2023.9960",
        "title": "Pharmacological characterization of mdma_2025_x29 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2023.5673",
        "title": "Pharmacological characterization of mdma_2025_x29 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827247"
  },
  "bzd_2025_x30": {
    "id": 97,
    "name": "Bzd 2025 X30",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 382.56,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US4652060",
    "safety_score": 65,
    "efficacy_score": 91,
    "drug_likeness": 91,
    "confidence_score": 79,
    "discovery_date": "2025-08-18T11:51:09.827253",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 50
    },
    "bioactivity_data": {
      "ic50_values": [
        69.23112364159765,
        177.71233114932744,
        457.84650520270986,
        608.2975309617359
      ],
      "ki_values": [
        44.193283642645135,
        372.87887476292286
      ],
      "ec50_values": [
        1170.9873125207996,
        807.255893197991,
        289.1728574465441,
        131.49418306075066
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound bzd_2025_x30 shows promising activity in Research Phase applications."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.6297",
        "title": "Pharmacological characterization of bzd_2025_x30 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2022.7850",
        "title": "Pharmacological characterization of bzd_2025_x30 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 90
      },
      {
        "doi": "10.1038/nature.2022.9683",
        "title": "Pharmacological characterization of bzd_2025_x30 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 98
      },
      {
        "doi": "10.1038/nature.2020.5845",
        "title": "Pharmacological characterization of bzd_2025_x30 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 85
      },
      {
        "doi": "10.1016/j.neuropharm.2023.3726",
        "title": "Pharmacological characterization of bzd_2025_x30 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827288"
  },
  "bzd_2025_z31": {
    "id": 98,
    "name": "Bzd 2025 Z31",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 333.74,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US4902675",
    "safety_score": 65,
    "efficacy_score": 82,
    "drug_likeness": 79,
    "confidence_score": 88,
    "discovery_date": "2025-02-06T11:51:09.827293",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 86
    },
    "bioactivity_data": {
      "ic50_values": [
        260.39052378466215,
        611.415587688554,
        338.2662401135099
      ],
      "ki_values": [
        236.60184703877928,
        18.753519030777404,
        314.52951781162994
      ],
      "ec50_values": [
        517.0224724732984,
        883.0284744823633,
        1464.2967205284049
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.9974",
        "title": "Pharmacological characterization of bzd_2025_z31 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 85
      },
      {
        "doi": "10.1126/science.2023.9792",
        "title": "Pharmacological characterization of bzd_2025_z31 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 93
      },
      {
        "doi": "10.1126/science.2023.6508",
        "title": "Pharmacological characterization of bzd_2025_z31 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 94
      },
      {
        "doi": "10.1038/nature.2021.1572",
        "title": "Pharmacological characterization of bzd_2025_z31 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 85
      },
      {
        "doi": "10.1126/science.2021.1888",
        "title": "Pharmacological characterization of bzd_2025_z31 and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827334"
  },
  "psi_2025_z32": {
    "id": 99,
    "name": "Psi 2025 Z32",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 266.18,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 85,
    "efficacy_score": 78,
    "drug_likeness": 76,
    "confidence_score": 83,
    "discovery_date": "2025-05-26T11:51:09.827339",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 52
    },
    "bioactivity_data": {
      "ic50_values": [
        134.90100063944058,
        882.4314095176665
      ],
      "ki_values": [
        208.9308335733117
      ],
      "ec50_values": [
        1927.7047886700382
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound psi_2025_z32 shows promising activity in Discovery Phase applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2020.5775",
        "title": "Pharmacological characterization of psi_2025_z32 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 88
      },
      {
        "doi": "10.1126/science.2024.7574",
        "title": "Pharmacological characterization of psi_2025_z32 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 95
      },
      {
        "doi": "10.1126/science.2022.5967",
        "title": "Pharmacological characterization of psi_2025_z32 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827370"
  },
  "mdma_2024_b33": {
    "id": 100,
    "name": "Mdma 2024 B33",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 158.1,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US2755382",
    "safety_score": 94,
    "efficacy_score": 69,
    "drug_likeness": 66,
    "confidence_score": 98,
    "discovery_date": "2025-06-20T11:51:09.827375",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 55
    },
    "bioactivity_data": {
      "ic50_values": [
        785.731103092616,
        729.0577877079237,
        698.530051267485,
        335.88202714090124
      ],
      "ki_values": [
        11.279995157674986,
        354.36561108002843,
        338.23807129181944
      ],
      "ec50_values": [
        1296.4804652810542,
        922.8735555107572,
        1406.7097192968538
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2020.6737",
        "title": "Pharmacological characterization of mdma_2024_b33 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 95
      },
      {
        "doi": "10.1126/science.2024.5908",
        "title": "Pharmacological characterization of mdma_2024_b33 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 93
      },
      {
        "doi": "10.1016/j.neuropharm.2020.3025",
        "title": "Pharmacological characterization of mdma_2024_b33 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827405"
  },
  "mdma_2024_a34": {
    "id": 101,
    "name": "Mdma 2024 A34",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 491.04,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US2096881",
    "safety_score": 89,
    "efficacy_score": 91,
    "drug_likeness": 81,
    "confidence_score": 80,
    "discovery_date": "2025-04-11T11:51:09.827410",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 72
    },
    "bioactivity_data": {
      "ic50_values": [
        493.1660306032972
      ],
      "ki_values": [
        483.43205536809035,
        272.21318499395807
      ],
      "ec50_values": [
        1995.3578258155253,
        1123.2315728219307,
        1573.5573357997887,
        500.1421701016766
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.1081",
        "title": "Pharmacological characterization of mdma_2024_a34 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 86
      },
      {
        "doi": "10.1126/science.2024.8178",
        "title": "Pharmacological characterization of mdma_2024_a34 and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 98
      },
      {
        "doi": "10.1126/science.2022.1795",
        "title": "Pharmacological characterization of mdma_2024_a34 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 90
      },
      {
        "doi": "10.1016/j.neuropharm.2023.7212",
        "title": "Pharmacological characterization of mdma_2024_a34 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827446"
  },
  "bzd_2025_z35": {
    "id": 102,
    "name": "Bzd 2025 Z35",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 261.26,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US6843109",
    "safety_score": 87,
    "efficacy_score": 69,
    "drug_likeness": 85,
    "confidence_score": 82,
    "discovery_date": "2024-11-08T11:51:09.827452",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 84
    },
    "bioactivity_data": {
      "ic50_values": [
        8.936239282331556,
        709.5747629484684,
        589.3831145195629,
        634.9270125695223,
        315.42412845067344
      ],
      "ki_values": [
        197.2841994277136
      ],
      "ec50_values": [
        376.2204977767455,
        1703.3432816862219,
        641.224033041503,
        1038.2361041427102
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2020.3021",
        "title": "Pharmacological characterization of bzd_2025_z35 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 88
      },
      {
        "doi": "10.1016/j.neuropharm.2022.5757",
        "title": "Pharmacological characterization of bzd_2025_z35 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 88
      },
      {
        "doi": "10.1124/jpet.2020.2902",
        "title": "Pharmacological characterization of bzd_2025_z35 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827483"
  },
  "mdma_2024_b36": {
    "id": 103,
    "name": "Mdma 2024 B36",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 166.91,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US8920941",
    "safety_score": 66,
    "efficacy_score": 78,
    "drug_likeness": 76,
    "confidence_score": 83,
    "discovery_date": "2025-02-12T11:51:09.827488",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 80
    },
    "bioactivity_data": {
      "ic50_values": [
        564.4288169061788,
        736.673535900152,
        995.1205019377328,
        725.4159599428964
      ],
      "ki_values": [
        125.15721426624307
      ],
      "ec50_values": [
        1658.2524574391703,
        934.7872653865438,
        514.1198590207792
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2022.1634",
        "title": "Pharmacological characterization of mdma_2024_b36 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 94
      },
      {
        "doi": "10.1124/jpet.2022.4974",
        "title": "Pharmacological characterization of mdma_2024_b36 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827516"
  },
  "ket_2024_a37": {
    "id": 104,
    "name": "Ket 2024 A37",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 236.8,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US3353836",
    "safety_score": 81,
    "efficacy_score": 74,
    "drug_likeness": 84,
    "confidence_score": 74,
    "discovery_date": "2024-11-14T11:51:09.827521",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 67
    },
    "bioactivity_data": {
      "ic50_values": [
        418.26017208532147,
        868.1343143056173,
        206.49570177160768,
        563.7700830003338
      ],
      "ki_values": [
        206.95880900037653,
        142.10926165882904,
        19.188290924397343
      ],
      "ec50_values": [
        84.06290887229815,
        283.63103375198403
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2021.1249",
        "title": "Pharmacological characterization of ket_2024_a37 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 94
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827548"
  },
  "psi_2024_c38": {
    "id": 105,
    "name": "Psi 2024 C38",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 429.28,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US9066373",
    "safety_score": 71,
    "efficacy_score": 74,
    "drug_likeness": 94,
    "confidence_score": 92,
    "discovery_date": "2025-01-29T11:51:09.827556",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 57
    },
    "bioactivity_data": {
      "ic50_values": [
        831.9835622799899,
        939.2756609513505
      ],
      "ki_values": [
        314.744097758594,
        436.5821227599852,
        164.41414516830616
      ],
      "ec50_values": [
        1071.1529418714065,
        1703.4554272814553,
        545.5714995214013,
        1021.2018234327425
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound psi_2024_c38 shows promising activity in Preclinical applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2020.5355",
        "title": "Pharmacological characterization of psi_2024_c38 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 85
      },
      {
        "doi": "10.1124/jpet.2021.3203",
        "title": "Pharmacological characterization of psi_2024_c38 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 97
      },
      {
        "doi": "10.1124/jpet.2021.4689",
        "title": "Pharmacological characterization of psi_2024_c38 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 87
      },
      {
        "doi": "10.1016/j.neuropharm.2022.4189",
        "title": "Pharmacological characterization of psi_2024_c38 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1038/nature.2020.3933",
        "title": "Pharmacological characterization of psi_2024_c38 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827595"
  },
  "ket_2025_x39": {
    "id": 106,
    "name": "Ket 2025 X39",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 204.99,
    "therapeutic_area": "Research Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 92,
    "efficacy_score": 87,
    "drug_likeness": 88,
    "confidence_score": 93,
    "discovery_date": "2025-02-06T11:51:09.827600",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 82
    },
    "bioactivity_data": {
      "ic50_values": [
        871.1049194578912,
        263.90419639792503,
        125.93568933046845,
        851.0249557082878
      ],
      "ki_values": [
        144.82884407038233
      ],
      "ec50_values": [
        1749.5239629457703,
        320.79271045940374,
        465.8357670416926,
        992.852224312409
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound ket_2025_x39 shows promising activity in Research Phase applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.7892",
        "title": "Pharmacological characterization of ket_2025_x39 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 88
      },
      {
        "doi": "10.1021/jmedchem.2020.6649",
        "title": "Pharmacological characterization of ket_2025_x39 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 96
      },
      {
        "doi": "10.1038/nature.2023.1870",
        "title": "Pharmacological characterization of ket_2025_x39 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 91
      },
      {
        "doi": "10.1038/nature.2024.7667",
        "title": "Pharmacological characterization of ket_2025_x39 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 87
      },
      {
        "doi": "10.1038/nature.2020.4459",
        "title": "Pharmacological characterization of ket_2025_x39 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827636"
  },
  "ket_2024_c40": {
    "id": 107,
    "name": "Ket 2024 C40",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 468.22,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US6286745",
    "safety_score": 89,
    "efficacy_score": 81,
    "drug_likeness": 68,
    "confidence_score": 89,
    "discovery_date": "2025-02-26T11:51:09.827641",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 89
    },
    "bioactivity_data": {
      "ic50_values": [
        115.85263915457885,
        564.7910343308936
      ],
      "ki_values": [
        146.0987643706444,
        289.3204436019847,
        21.885934417190953
      ],
      "ec50_values": [
        865.9564937380645,
        1218.0345438474774,
        717.5228042675152,
        190.2774192013213
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.8553",
        "title": "Pharmacological characterization of ket_2024_c40 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 94
      },
      {
        "doi": "10.1126/science.2020.6506",
        "title": "Pharmacological characterization of ket_2024_c40 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827669"
  },
  "stim_2025_x41": {
    "id": 108,
    "name": "Stim 2025 X41",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 332.43,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US9417622",
    "safety_score": 86,
    "efficacy_score": 90,
    "drug_likeness": 91,
    "confidence_score": 70,
    "discovery_date": "2025-05-15T11:51:09.827674",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 52
    },
    "bioactivity_data": {
      "ic50_values": [
        767.6879640821785,
        520.9106390874583,
        431.7732597405895,
        271.234751226173,
        909.6669330179718
      ],
      "ki_values": [
        283.491401739153,
        6.673641843538461,
        330.7088897040435
      ],
      "ec50_values": [
        654.8848330465819,
        1695.6594365821943,
        74.63693974837733
      ]
    },
    "research_notes": [
      "Compound stim_2025_x41 shows promising activity in Novel Therapy applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2020.5488",
        "title": "Pharmacological characterization of stim_2025_x41 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 96
      },
      {
        "doi": "10.1124/jpet.2023.4726",
        "title": "Pharmacological characterization of stim_2025_x41 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 98
      },
      {
        "doi": "10.1021/jmedchem.2020.8291",
        "title": "Pharmacological characterization of stim_2025_x41 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1021/jmedchem.2022.5359",
        "title": "Pharmacological characterization of stim_2025_x41 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827715"
  },
  "stim_2024_b42": {
    "id": 109,
    "name": "Stim 2024 B42",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 401.37,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US9996752",
    "safety_score": 89,
    "efficacy_score": 92,
    "drug_likeness": 59,
    "confidence_score": 84,
    "discovery_date": "2025-04-09T11:51:09.827721",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 67
    },
    "bioactivity_data": {
      "ic50_values": [
        441.12340112101833,
        486.68802535764314,
        376.6763742810097,
        406.7028259444739
      ],
      "ki_values": [
        425.706225044847,
        12.547871531507852,
        64.7742583372862
      ],
      "ec50_values": [
        636.880827364136,
        1472.8981754284173
      ]
    },
    "research_notes": [
      "Compound stim_2024_b42 shows promising activity in Novel Therapy applications.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2022.8640",
        "title": "Pharmacological characterization of stim_2024_b42 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 90
      },
      {
        "doi": "10.1038/nature.2024.2460",
        "title": "Pharmacological characterization of stim_2024_b42 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 86
      },
      {
        "doi": "10.1038/nature.2024.3797",
        "title": "Pharmacological characterization of stim_2024_b42 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 87
      },
      {
        "doi": "10.1016/j.neuropharm.2024.3658",
        "title": "Pharmacological characterization of stim_2024_b42 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827755"
  },
  "opi_2024_b43": {
    "id": 110,
    "name": "Opi 2024 B43",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 170.62,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US7803591",
    "safety_score": 91,
    "efficacy_score": 88,
    "drug_likeness": 60,
    "confidence_score": 76,
    "discovery_date": "2024-10-07T11:51:09.827761",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 60
    },
    "bioactivity_data": {
      "ic50_values": [
        64.25043862286392,
        275.61134107867497,
        666.7542238970299,
        176.54274778939032
      ],
      "ki_values": [
        196.65058634228828,
        96.90388242171109
      ],
      "ec50_values": [
        328.0243005971122,
        1206.157340321327,
        104.51381942460517
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound opi_2024_b43 shows promising activity in Novel Therapy applications."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2022.3616",
        "title": "Pharmacological characterization of opi_2024_b43 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827785"
  },
  "anti_2025_z44": {
    "id": 111,
    "name": "Anti 2025 Z44",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 230.95,
    "therapeutic_area": "Novel Therapy",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US3012769",
    "safety_score": 77,
    "efficacy_score": 90,
    "drug_likeness": 63,
    "confidence_score": 83,
    "discovery_date": "2025-03-02T11:51:09.827791",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 57
    },
    "bioactivity_data": {
      "ic50_values": [
        474.8534440748725,
        587.1482122795057,
        127.71241044848377,
        665.311248547091
      ],
      "ki_values": [
        496.65747603653784
      ],
      "ec50_values": [
        124.22062842184575,
        1218.2924090042427,
        1170.6704533978557
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound anti_2025_z44 shows promising activity in Novel Therapy applications."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.5591",
        "title": "Pharmacological characterization of anti_2025_z44 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 95
      },
      {
        "doi": "10.1038/nature.2024.5118",
        "title": "Pharmacological characterization of anti_2025_z44 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 94
      },
      {
        "doi": "10.1016/j.neuropharm.2021.8503",
        "title": "Pharmacological characterization of anti_2025_z44 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827831"
  },
  "psi_2024_a45": {
    "id": 112,
    "name": "Psi 2024 A45",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 379.59,
    "therapeutic_area": "Preclinical",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US7097328",
    "safety_score": 73,
    "efficacy_score": 97,
    "drug_likeness": 93,
    "confidence_score": 71,
    "discovery_date": "2024-10-21T11:51:09.827836",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 53
    },
    "bioactivity_data": {
      "ic50_values": [
        456.36417634579084,
        790.8266752708183,
        838.805667691344,
        843.6199638687577,
        142.88969139635861
      ],
      "ki_values": [
        128.3976629911666
      ],
      "ec50_values": [
        115.62413352234427,
        1130.0081040067935
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.6322",
        "title": "Pharmacological characterization of psi_2024_a45 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 98
      },
      {
        "doi": "10.1124/jpet.2020.1464",
        "title": "Pharmacological characterization of psi_2024_a45 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 93
      },
      {
        "doi": "10.1124/jpet.2021.1366",
        "title": "Pharmacological characterization of psi_2024_a45 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827869"
  },
  "mdma_2024_b46": {
    "id": 113,
    "name": "Mdma 2024 B46",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 193.24,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US9934314",
    "safety_score": 68,
    "efficacy_score": 70,
    "drug_likeness": 72,
    "confidence_score": 98,
    "discovery_date": "2024-11-18T11:51:09.827877",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 89
    },
    "bioactivity_data": {
      "ic50_values": [
        254.78296049750307,
        955.0323982795986
      ],
      "ki_values": [
        357.2748709197903
      ],
      "ec50_values": [
        1438.6689878393308,
        1053.7104151402193
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound mdma_2024_b46 shows promising activity in Research Phase applications."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2024.1407",
        "title": "Pharmacological characterization of mdma_2024_b46 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 96
      },
      {
        "doi": "10.1016/j.neuropharm.2024.4340",
        "title": "Pharmacological characterization of mdma_2024_b46 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 97
      },
      {
        "doi": "10.1126/science.2023.8848",
        "title": "Pharmacological characterization of mdma_2024_b46 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 92
      },
      {
        "doi": "10.1016/j.neuropharm.2024.1109",
        "title": "Pharmacological characterization of mdma_2024_b46 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827909"
  },
  "ket_2024_c47": {
    "id": 114,
    "name": "Ket 2024 C47",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 323.85,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US7786322",
    "safety_score": 71,
    "efficacy_score": 77,
    "drug_likeness": 59,
    "confidence_score": 89,
    "discovery_date": "2025-03-11T11:51:09.827914",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 80
    },
    "bioactivity_data": {
      "ic50_values": [
        201.28835039603288,
        528.0773154202867
      ],
      "ki_values": [
        205.9363969514226
      ],
      "ec50_values": [
        1941.7663724352153
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.2771",
        "title": "Pharmacological characterization of ket_2024_c47 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827938"
  },
  "stim_2024_b48": {
    "id": 115,
    "name": "Stim 2024 B48",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 466.91,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US5043132",
    "safety_score": 92,
    "efficacy_score": 87,
    "drug_likeness": 83,
    "confidence_score": 76,
    "discovery_date": "2025-06-09T11:51:09.827947",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 89
    },
    "bioactivity_data": {
      "ic50_values": [
        638.0096460485462,
        278.75434930655587,
        749.6013651375131
      ],
      "ki_values": [
        2.2620358750546083
      ],
      "ec50_values": [
        818.0073914565289,
        134.8808507955012,
        389.8952792456488
      ]
    },
    "research_notes": [
      "Compound stim_2024_b48 shows promising activity in Preclinical applications.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2024.8414",
        "title": "Pharmacological characterization of stim_2024_b48 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 91
      },
      {
        "doi": "10.1038/nature.2021.5010",
        "title": "Pharmacological characterization of stim_2024_b48 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T11:51:09.827973"
  },
  "ket_2025_y49": {
    "id": 116,
    "name": "Ket 2025 Y49",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 410.37,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US2460656",
    "safety_score": 69,
    "efficacy_score": 67,
    "drug_likeness": 87,
    "confidence_score": 77,
    "discovery_date": "2024-09-27T11:51:09.827979",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 87
    },
    "bioactivity_data": {
      "ic50_values": [
        820.1011786555445,
        233.44141413426854,
        497.1007379180879
      ],
      "ki_values": [
        190.69963969071748,
        143.59233592981826
      ],
      "ec50_values": [
        1643.253844901559,
        1479.791895437389,
        412.1616417903736
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound ket_2025_y49 shows promising activity in Novel Therapy applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2022.4186",
        "title": "Pharmacological characterization of ket_2025_y49 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 92
      },
      {
        "doi": "10.1126/science.2023.2453",
        "title": "Pharmacological characterization of ket_2025_y49 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828008"
  },
  "psi_2025_y50": {
    "id": 117,
    "name": "Psi 2025 Y50",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 434.77,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US4888216",
    "safety_score": 94,
    "efficacy_score": 77,
    "drug_likeness": 76,
    "confidence_score": 88,
    "discovery_date": "2025-03-30T11:51:09.828013",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 89
    },
    "bioactivity_data": {
      "ic50_values": [
        866.7993355269572,
        407.64885803326064,
        608.800117850287
      ],
      "ki_values": [
        112.48655272117902,
        127.0597584251937
      ],
      "ec50_values": [
        1887.7663537622982,
        39.89715016112938
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.7345",
        "title": "Pharmacological characterization of psi_2025_y50 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 93
      },
      {
        "doi": "10.1021/jmedchem.2021.1892",
        "title": "Pharmacological characterization of psi_2025_y50 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828042"
  },
  "psi_2025_z51": {
    "id": 118,
    "name": "Psi 2025 Z51",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 200.04,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US1239319",
    "safety_score": 77,
    "efficacy_score": 93,
    "drug_likeness": 95,
    "confidence_score": 75,
    "discovery_date": "2025-04-16T11:51:09.828047",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 85
    },
    "bioactivity_data": {
      "ic50_values": [
        307.40759502250575,
        875.1454597891128,
        917.493157762183
      ],
      "ki_values": [
        411.1212763387499,
        70.1033417391299,
        58.694275640369824
      ],
      "ec50_values": [
        1087.1692399318442,
        1998.220248416136
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2020.4168",
        "title": "Pharmacological characterization of psi_2025_z51 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 85
      },
      {
        "doi": "10.1016/j.neuropharm.2022.8617",
        "title": "Pharmacological characterization of psi_2025_z51 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828076"
  },
  "psi_2024_a52": {
    "id": 119,
    "name": "Psi 2024 A52",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 153.94,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US2488305",
    "safety_score": 89,
    "efficacy_score": 69,
    "drug_likeness": 55,
    "confidence_score": 73,
    "discovery_date": "2025-04-09T11:51:09.828081",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 90
    },
    "bioactivity_data": {
      "ic50_values": [
        25.678148680333443,
        943.7891839668773,
        971.3555783110882
      ],
      "ki_values": [
        469.33739051478307
      ],
      "ec50_values": [
        655.2785828720614
      ]
    },
    "research_notes": [
      "Compound psi_2024_a52 shows promising activity in Discovery Phase applications.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2022.1372",
        "title": "Pharmacological characterization of psi_2024_a52 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828106"
  },
  "stim_2024_c53": {
    "id": 120,
    "name": "Stim 2024 C53",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 363.12,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US1686301",
    "safety_score": 61,
    "efficacy_score": 79,
    "drug_likeness": 95,
    "confidence_score": 72,
    "discovery_date": "2025-04-29T11:51:09.828111",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 78
    },
    "bioactivity_data": {
      "ic50_values": [
        141.27376947338905,
        229.9506777199396
      ],
      "ki_values": [
        60.1895426415491,
        198.28847861653034
      ],
      "ec50_values": [
        1345.1513337571755,
        538.4913780926116,
        1801.67922608778
      ]
    },
    "research_notes": [
      "Compound stim_2024_c53 shows promising activity in Discovery Phase applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2021.4506",
        "title": "Pharmacological characterization of stim_2024_c53 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 94
      },
      {
        "doi": "10.1038/nature.2023.8908",
        "title": "Pharmacological characterization of stim_2024_c53 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 95
      },
      {
        "doi": "10.1021/jmedchem.2021.5058",
        "title": "Pharmacological characterization of stim_2024_c53 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828144"
  },
  "ket_2025_x54": {
    "id": 121,
    "name": "Ket 2025 X54",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 279.52,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US7683841",
    "safety_score": 72,
    "efficacy_score": 71,
    "drug_likeness": 87,
    "confidence_score": 72,
    "discovery_date": "2025-06-10T11:51:09.828149",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 84
    },
    "bioactivity_data": {
      "ic50_values": [
        545.3859134188325,
        557.633545582756,
        166.48894946989796,
        64.18529762702981,
        788.6953225010014
      ],
      "ki_values": [
        496.72724059162374,
        102.17649684563162
      ],
      "ec50_values": [
        516.2980840767117,
        47.15128264284735,
        914.5999173401167,
        1428.0372160406375
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.6782",
        "title": "Pharmacological characterization of ket_2025_x54 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828177"
  },
  "ket_2025_y55": {
    "id": 122,
    "name": "Ket 2025 Y55",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 466.85,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 72,
    "efficacy_score": 79,
    "drug_likeness": 68,
    "confidence_score": 73,
    "discovery_date": "2024-09-25T11:51:09.828182",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 78
    },
    "bioactivity_data": {
      "ic50_values": [
        950.6652493134668,
        895.5222890631035,
        952.5236484748067,
        704.6451408060666,
        722.8429375008335
      ],
      "ki_values": [
        171.02196522869494,
        129.3436453342714,
        202.18601861703218
      ],
      "ec50_values": [
        735.2263370315187,
        1607.432102680922,
        1064.86633517133
      ]
    },
    "research_notes": [
      "Compound ket_2025_y55 shows promising activity in Research Phase applications.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2024.9899",
        "title": "Pharmacological characterization of ket_2025_y55 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2023.2900",
        "title": "Pharmacological characterization of ket_2025_y55 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828212"
  },
  "ket_2025_x56": {
    "id": 123,
    "name": "Ket 2025 X56",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 392.65,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US1259687",
    "safety_score": 68,
    "efficacy_score": 70,
    "drug_likeness": 93,
    "confidence_score": 86,
    "discovery_date": "2024-11-26T11:51:09.828217",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 88
    },
    "bioactivity_data": {
      "ic50_values": [
        159.16840419874998
      ],
      "ki_values": [
        164.33469752373674
      ],
      "ec50_values": [
        31.464110722887927,
        1684.975767278633,
        1625.0857500045663
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2024.4862",
        "title": "Pharmacological characterization of ket_2025_x56 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 93
      },
      {
        "doi": "10.1016/j.neuropharm.2021.8789",
        "title": "Pharmacological characterization of ket_2025_x56 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828249"
  },
  "anti_2024_a57": {
    "id": 124,
    "name": "Anti 2024 A57",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 269.03,
    "therapeutic_area": "Preclinical",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 83,
    "efficacy_score": 70,
    "drug_likeness": 87,
    "confidence_score": 80,
    "discovery_date": "2025-06-24T11:51:09.828253",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 67
    },
    "bioactivity_data": {
      "ic50_values": [
        89.06693368725318,
        428.49048045384217,
        583.2120162189002,
        458.9160571410766
      ],
      "ki_values": [
        390.22227805974666
      ],
      "ec50_values": [
        150.34327896496129,
        95.98271315221307
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound anti_2024_a57 shows promising activity in Preclinical applications.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2020.6335",
        "title": "Pharmacological characterization of anti_2024_a57 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 94
      },
      {
        "doi": "10.1126/science.2024.7235",
        "title": "Pharmacological characterization of anti_2024_a57 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 94
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828281"
  },
  "mdma_2024_c58": {
    "id": 125,
    "name": "Mdma 2024 C58",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 421.72,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US9716784",
    "safety_score": 78,
    "efficacy_score": 97,
    "drug_likeness": 84,
    "confidence_score": 94,
    "discovery_date": "2024-09-28T11:51:09.828289",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 72
    },
    "bioactivity_data": {
      "ic50_values": [
        370.3039143095514,
        900.62608975442,
        604.805650471765,
        6.02059587453119,
        782.8171622732164
      ],
      "ki_values": [
        146.44052869327652,
        191.19492183197127,
        347.7167932755484
      ],
      "ec50_values": [
        1381.7413875264297
      ]
    },
    "research_notes": [
      "Compound mdma_2024_c58 shows promising activity in Research Phase applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2021.8698",
        "title": "Pharmacological characterization of mdma_2024_c58 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 93
      },
      {
        "doi": "10.1126/science.2023.5627",
        "title": "Pharmacological characterization of mdma_2024_c58 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1038/nature.2023.6412",
        "title": "Pharmacological characterization of mdma_2024_c58 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1038/nature.2022.8628",
        "title": "Pharmacological characterization of mdma_2024_c58 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 90
      },
      {
        "doi": "10.1016/j.neuropharm.2024.7585",
        "title": "Pharmacological characterization of mdma_2024_c58 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828325"
  },
  "lsd_2024_c59": {
    "id": 126,
    "name": "Lsd 2024 C59",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 393.06,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US4836943",
    "safety_score": 75,
    "efficacy_score": 69,
    "drug_likeness": 66,
    "confidence_score": 96,
    "discovery_date": "2025-05-06T11:51:09.828330",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 76
    },
    "bioactivity_data": {
      "ic50_values": [
        446.6882526406178,
        830.6376525025114,
        742.8741823707578,
        168.05606274950694,
        698.1561304410164
      ],
      "ki_values": [
        381.99885310488764,
        441.4937292104843,
        110.3933519221789
      ],
      "ec50_values": [
        1963.179288929995
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2022.8540",
        "title": "Pharmacological characterization of lsd_2024_c59 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 87
      },
      {
        "doi": "10.1038/nature.2022.2703",
        "title": "Pharmacological characterization of lsd_2024_c59 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 89
      },
      {
        "doi": "10.1038/nature.2023.8280",
        "title": "Pharmacological characterization of lsd_2024_c59 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 91
      },
      {
        "doi": "10.1038/nature.2023.2813",
        "title": "Pharmacological characterization of lsd_2024_c59 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 88
      },
      {
        "doi": "10.1016/j.neuropharm.2023.3254",
        "title": "Pharmacological characterization of lsd_2024_c59 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828369"
  },
  "stim_2025_x60": {
    "id": 127,
    "name": "Stim 2025 X60",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 259.6,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 80,
    "efficacy_score": 68,
    "drug_likeness": 73,
    "confidence_score": 82,
    "discovery_date": "2025-03-13T11:51:09.828374",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 66
    },
    "bioactivity_data": {
      "ic50_values": [
        107.79288224621592,
        757.0040943406142,
        69.77905393665331,
        31.531395117821383
      ],
      "ki_values": [
        43.13413320559278
      ],
      "ec50_values": [
        792.9401710806661
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.2402",
        "title": "Pharmacological characterization of stim_2025_x60 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 88
      },
      {
        "doi": "10.1016/j.neuropharm.2023.5437",
        "title": "Pharmacological characterization of stim_2025_x60 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 93
      },
      {
        "doi": "10.1016/j.neuropharm.2023.6637",
        "title": "Pharmacological characterization of stim_2025_x60 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828408"
  },
  "lsd_2025_x61": {
    "id": 128,
    "name": "Lsd 2025 X61",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 339.19,
    "therapeutic_area": "Discovery Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 90,
    "efficacy_score": 89,
    "drug_likeness": 82,
    "confidence_score": 92,
    "discovery_date": "2025-05-21T11:51:09.828413",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 54
    },
    "bioactivity_data": {
      "ic50_values": [
        435.66176344280376,
        235.72180023002855,
        561.0090683227402,
        934.1444054847552,
        987.679248733163
      ],
      "ki_values": [
        48.8977391808932
      ],
      "ec50_values": [
        35.150446512642,
        1042.935881611929,
        1439.2490517504784
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound lsd_2025_x61 shows promising activity in Discovery Phase applications."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2022.8686",
        "title": "Pharmacological characterization of lsd_2025_x61 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 96
      },
      {
        "doi": "10.1016/j.neuropharm.2020.5773",
        "title": "Pharmacological characterization of lsd_2025_x61 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 88
      },
      {
        "doi": "10.1038/nature.2023.3154",
        "title": "Pharmacological characterization of lsd_2025_x61 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828443"
  },
  "opi_2025_z62": {
    "id": 129,
    "name": "Opi 2025 Z62",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 412.31,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US4447871",
    "safety_score": 89,
    "efficacy_score": 74,
    "drug_likeness": 57,
    "confidence_score": 89,
    "discovery_date": "2025-08-22T11:51:09.828448",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 63
    },
    "bioactivity_data": {
      "ic50_values": [
        240.6105681225608,
        792.830755744384,
        153.78390091369076,
        721.9868367246628,
        816.735096149972
      ],
      "ki_values": [
        294.69381593375635,
        190.26053770313754,
        315.0342950044026
      ],
      "ec50_values": [
        424.52167389349273,
        675.5963347843004
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2022.9619",
        "title": "Pharmacological characterization of opi_2025_z62 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828475"
  },
  "opi_2025_y63": {
    "id": 130,
    "name": "Opi 2025 Y63",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 454.94,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US3491136",
    "safety_score": 75,
    "efficacy_score": 75,
    "drug_likeness": 62,
    "confidence_score": 79,
    "discovery_date": "2025-01-27T11:51:09.828480",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 56
    },
    "bioactivity_data": {
      "ic50_values": [
        18.99806517372622,
        686.5693956512829,
        757.7488673648493,
        504.01429048819597
      ],
      "ki_values": [
        120.35468382455753,
        206.0097341868424,
        9.36070392295405
      ],
      "ec50_values": [
        983.3421639193268,
        1921.8921584232205,
        512.3875759234717
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2024.6793",
        "title": "Pharmacological characterization of opi_2025_y63 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 89
      },
      {
        "doi": "10.1016/j.neuropharm.2020.1136",
        "title": "Pharmacological characterization of opi_2025_y63 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 90
      },
      {
        "doi": "10.1021/jmedchem.2020.8150",
        "title": "Pharmacological characterization of opi_2025_y63 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828511"
  },
  "anti_2024_b64": {
    "id": 131,
    "name": "Anti 2024 B64",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 492.14,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US4787041",
    "safety_score": 95,
    "efficacy_score": 80,
    "drug_likeness": 86,
    "confidence_score": 87,
    "discovery_date": "2025-06-17T11:51:09.828516",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 87
    },
    "bioactivity_data": {
      "ic50_values": [
        225.54032633978318,
        130.6695008539382,
        461.0523538935517,
        457.1078585342164,
        941.9779528744415
      ],
      "ki_values": [
        324.4112868614607,
        217.55320557143258,
        131.2751740521735
      ],
      "ec50_values": [
        1882.9764268320118
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound anti_2024_b64 shows promising activity in Novel Therapy applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2024.3337",
        "title": "Pharmacological characterization of anti_2024_b64 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 93
      },
      {
        "doi": "10.1126/science.2020.1895",
        "title": "Pharmacological characterization of anti_2024_b64 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 87
      },
      {
        "doi": "10.1126/science.2023.2082",
        "title": "Pharmacological characterization of anti_2024_b64 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2023.1165",
        "title": "Pharmacological characterization of anti_2024_b64 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 96
      },
      {
        "doi": "10.1016/j.neuropharm.2020.9372",
        "title": "Pharmacological characterization of anti_2024_b64 and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828556"
  },
  "psi_2025_z65": {
    "id": 132,
    "name": "Psi 2025 Z65",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 445.56,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 74,
    "efficacy_score": 74,
    "drug_likeness": 63,
    "confidence_score": 84,
    "discovery_date": "2025-05-30T11:51:09.828560",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 73
    },
    "bioactivity_data": {
      "ic50_values": [
        362.44398119517024
      ],
      "ki_values": [
        385.53477465924874,
        3.0589605102640407,
        210.77703529344544
      ],
      "ec50_values": [
        69.33569151701536,
        378.2143603835061,
        1784.8545142949117,
        821.2629085425998
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.4882",
        "title": "Pharmacological characterization of psi_2025_z65 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 94
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828585"
  },
  "anti_2025_z66": {
    "id": 133,
    "name": "Anti 2025 Z66",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 294.61,
    "therapeutic_area": "Discovery Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US4880120",
    "safety_score": 79,
    "efficacy_score": 82,
    "drug_likeness": 77,
    "confidence_score": 82,
    "discovery_date": "2025-09-15T11:51:09.828591",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 59
    },
    "bioactivity_data": {
      "ic50_values": [
        202.61692218843243,
        405.10635563839264,
        371.8793441481796,
        128.36380257768548,
        694.324158927128
      ],
      "ki_values": [
        128.92993656203456,
        467.35883658156973,
        303.780285514991
      ],
      "ec50_values": [
        813.9467709447034,
        901.5901254833221,
        316.18535520415344,
        1202.01923943389
      ]
    },
    "research_notes": [
      "Compound anti_2025_z66 shows promising activity in Discovery Phase applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2021.2508",
        "title": "Pharmacological characterization of anti_2025_z66 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 95
      },
      {
        "doi": "10.1016/j.neuropharm.2021.3946",
        "title": "Pharmacological characterization of anti_2025_z66 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828621"
  },
  "anti_2025_z67": {
    "id": 134,
    "name": "Anti 2025 Z67",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 452.95,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 72,
    "efficacy_score": 80,
    "drug_likeness": 59,
    "confidence_score": 85,
    "discovery_date": "2024-12-09T11:51:09.828626",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 87
    },
    "bioactivity_data": {
      "ic50_values": [
        897.265312461553,
        98.91025261800361
      ],
      "ki_values": [
        456.646005009389,
        106.20465676799627
      ],
      "ec50_values": [
        483.08813632219056,
        1654.799725718735,
        214.39092074540568
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2023.3846",
        "title": "Pharmacological characterization of anti_2025_z67 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 87
      },
      {
        "doi": "10.1021/jmedchem.2024.3409",
        "title": "Pharmacological characterization of anti_2025_z67 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 96
      },
      {
        "doi": "10.1021/jmedchem.2020.2847",
        "title": "Pharmacological characterization of anti_2025_z67 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 86
      },
      {
        "doi": "10.1021/jmedchem.2020.3908",
        "title": "Pharmacological characterization of anti_2025_z67 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 96
      },
      {
        "doi": "10.1038/nature.2024.1027",
        "title": "Pharmacological characterization of anti_2025_z67 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828661"
  },
  "opi_2024_a68": {
    "id": 135,
    "name": "Opi 2024 A68",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 485.42,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US1341724",
    "safety_score": 62,
    "efficacy_score": 92,
    "drug_likeness": 61,
    "confidence_score": 98,
    "discovery_date": "2024-10-30T11:51:09.828669",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 87
    },
    "bioactivity_data": {
      "ic50_values": [
        529.2980809748323,
        664.2196961225636,
        878.8603860699459,
        248.52349997905026
      ],
      "ki_values": [
        492.6753030593088
      ],
      "ec50_values": [
        1141.1606340137846,
        1843.5274992772443
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound opi_2024_a68 shows promising activity in Discovery Phase applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.7930",
        "title": "Pharmacological characterization of opi_2024_a68 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 90
      },
      {
        "doi": "10.1016/j.neuropharm.2021.7608",
        "title": "Pharmacological characterization of opi_2024_a68 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 91
      },
      {
        "doi": "10.1124/jpet.2021.9499",
        "title": "Pharmacological characterization of opi_2024_a68 and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828703"
  },
  "ket_2025_z69": {
    "id": 136,
    "name": "Ket 2025 Z69",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 467.99,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 83,
    "efficacy_score": 89,
    "drug_likeness": 67,
    "confidence_score": 91,
    "discovery_date": "2025-04-13T11:51:09.828708",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 56
    },
    "bioactivity_data": {
      "ic50_values": [
        162.217033457005,
        975.6762085969315
      ],
      "ki_values": [
        344.61059589716956,
        211.48296983569216,
        394.3869886923106
      ],
      "ec50_values": [
        86.65890518174041,
        1081.649842011908,
        136.52204159326547,
        1229.863520419782
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2024.7969",
        "title": "Pharmacological characterization of ket_2025_z69 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 93
      },
      {
        "doi": "10.1021/jmedchem.2024.9247",
        "title": "Pharmacological characterization of ket_2025_z69 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828739"
  },
  "ket_2025_x70": {
    "id": 137,
    "name": "Ket 2025 X70",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 351.25,
    "therapeutic_area": "Preclinical",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US6824518",
    "safety_score": 61,
    "efficacy_score": 86,
    "drug_likeness": 79,
    "confidence_score": 84,
    "discovery_date": "2024-09-25T11:51:09.828744",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 70
    },
    "bioactivity_data": {
      "ic50_values": [
        9.409832244685555
      ],
      "ki_values": [
        461.4228841823972
      ],
      "ec50_values": [
        866.6645327693699,
        1865.7155012404396,
        1696.6893638910542,
        139.17059939384671
      ]
    },
    "research_notes": [
      "Compound ket_2025_x70 shows promising activity in Preclinical applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2022.6850",
        "title": "Pharmacological characterization of ket_2025_x70 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 85
      },
      {
        "doi": "10.1016/j.neuropharm.2020.5152",
        "title": "Pharmacological characterization of ket_2025_x70 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 97
      },
      {
        "doi": "10.1021/jmedchem.2021.3861",
        "title": "Pharmacological characterization of ket_2025_x70 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 87
      },
      {
        "doi": "10.1021/jmedchem.2023.8383",
        "title": "Pharmacological characterization of ket_2025_x70 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828779"
  },
  "lsd_2025_x71": {
    "id": 138,
    "name": "Lsd 2025 X71",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 252.64,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 67,
    "efficacy_score": 71,
    "drug_likeness": 84,
    "confidence_score": 90,
    "discovery_date": "2025-02-22T11:51:09.828784",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 88
    },
    "bioactivity_data": {
      "ic50_values": [
        517.3053046607253,
        398.2767745833171,
        857.1074161905569,
        965.3680676112815
      ],
      "ki_values": [
        55.18122882549028,
        416.35032043774174,
        233.58720188999948
      ],
      "ec50_values": [
        1497.8856473114001,
        1058.9460127964035
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2023.6377",
        "title": "Pharmacological characterization of lsd_2025_x71 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 97
      },
      {
        "doi": "10.1021/jmedchem.2024.7915",
        "title": "Pharmacological characterization of lsd_2025_x71 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 85
      },
      {
        "doi": "10.1016/j.neuropharm.2022.3507",
        "title": "Pharmacological characterization of lsd_2025_x71 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 96
      },
      {
        "doi": "10.1021/jmedchem.2021.2891",
        "title": "Pharmacological characterization of lsd_2025_x71 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828816"
  },
  "lsd_2024_b72": {
    "id": 139,
    "name": "Lsd 2024 B72",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 217.49,
    "therapeutic_area": "Discovery Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 71,
    "efficacy_score": 89,
    "drug_likeness": 56,
    "confidence_score": 96,
    "discovery_date": "2025-02-10T11:51:09.828821",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 57
    },
    "bioactivity_data": {
      "ic50_values": [
        983.6601968921498,
        459.3713646280609,
        709.7037674182404,
        518.3631214619674
      ],
      "ki_values": [
        454.62419296427385
      ],
      "ec50_values": [
        1704.1490346306682,
        157.3165959756738
      ]
    },
    "research_notes": [
      "Compound lsd_2024_b72 shows promising activity in Discovery Phase applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2024.5115",
        "title": "Pharmacological characterization of lsd_2024_b72 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 86
      },
      {
        "doi": "10.1016/j.neuropharm.2021.8341",
        "title": "Pharmacological characterization of lsd_2024_b72 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828848"
  },
  "stim_2024_a73": {
    "id": 140,
    "name": "Stim 2024 A73",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 354.24,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US7177688",
    "safety_score": 74,
    "efficacy_score": 69,
    "drug_likeness": 65,
    "confidence_score": 70,
    "discovery_date": "2024-11-07T11:51:09.828853",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 76
    },
    "bioactivity_data": {
      "ic50_values": [
        643.3447450956362,
        424.1406107052548
      ],
      "ki_values": [
        278.5373803855531
      ],
      "ec50_values": [
        233.67412054083874,
        1483.5568382586448,
        700.706829262617,
        552.21549274641
      ]
    },
    "research_notes": [
      "Compound stim_2024_a73 shows promising activity in Preclinical applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.8277",
        "title": "Pharmacological characterization of stim_2024_a73 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 89
      },
      {
        "doi": "10.1021/jmedchem.2024.7451",
        "title": "Pharmacological characterization of stim_2024_a73 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 98
      },
      {
        "doi": "10.1126/science.2024.5603",
        "title": "Pharmacological characterization of stim_2024_a73 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 87
      },
      {
        "doi": "10.1038/nature.2022.9223",
        "title": "Pharmacological characterization of stim_2024_a73 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828890"
  },
  "opi_2024_c74": {
    "id": 141,
    "name": "Opi 2024 C74",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 486.64,
    "therapeutic_area": "Research Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US2324864",
    "safety_score": 75,
    "efficacy_score": 71,
    "drug_likeness": 80,
    "confidence_score": 72,
    "discovery_date": "2025-03-18T11:51:09.828899",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 68
    },
    "bioactivity_data": {
      "ic50_values": [
        96.39460665298866
      ],
      "ki_values": [
        180.7713230142877
      ],
      "ec50_values": [
        911.8938593033929
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.3379",
        "title": "Pharmacological characterization of opi_2024_c74 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 85
      },
      {
        "doi": "10.1126/science.2022.4861",
        "title": "Pharmacological characterization of opi_2024_c74 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 95
      },
      {
        "doi": "10.1038/nature.2022.3325",
        "title": "Pharmacological characterization of opi_2024_c74 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 88
      },
      {
        "doi": "10.1124/jpet.2022.4381",
        "title": "Pharmacological characterization of opi_2024_c74 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 87
      },
      {
        "doi": "10.1021/jmedchem.2022.2405",
        "title": "Pharmacological characterization of opi_2024_c74 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828934"
  },
  "opi_2024_b75": {
    "id": 142,
    "name": "Opi 2024 B75",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 228.24,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US7833633",
    "safety_score": 93,
    "efficacy_score": 83,
    "drug_likeness": 78,
    "confidence_score": 84,
    "discovery_date": "2025-05-12T11:51:09.828939",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 84
    },
    "bioactivity_data": {
      "ic50_values": [
        17.71398040784776,
        643.0424128015333,
        698.3353338110433
      ],
      "ki_values": [
        103.46399932178876
      ],
      "ec50_values": [
        1959.9708248416455
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.2934",
        "title": "Pharmacological characterization of opi_2024_b75 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 97
      },
      {
        "doi": "10.1021/jmedchem.2020.6856",
        "title": "Pharmacological characterization of opi_2024_b75 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T11:51:09.828966"
  },
  "ket_2024_c76": {
    "id": 143,
    "name": "Ket 2024 C76",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 206.13,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US2025082",
    "safety_score": 72,
    "efficacy_score": 65,
    "drug_likeness": 74,
    "confidence_score": 73,
    "discovery_date": "2025-02-25T11:51:09.828971",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 78
    },
    "bioactivity_data": {
      "ic50_values": [
        430.36354755558426
      ],
      "ki_values": [
        409.9378010792854,
        418.48085437755475,
        43.69158658506919
      ],
      "ec50_values": [
        1900.1655025490347,
        928.3660223105859
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2021.4288",
        "title": "Pharmacological characterization of ket_2024_c76 and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 91
      },
      {
        "doi": "10.1016/j.neuropharm.2024.5132",
        "title": "Pharmacological characterization of ket_2024_c76 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 87
      },
      {
        "doi": "10.1021/jmedchem.2022.7417",
        "title": "Pharmacological characterization of ket_2024_c76 and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 96
      },
      {
        "doi": "10.1126/science.2020.4828",
        "title": "Pharmacological characterization of ket_2024_c76 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 94
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829003"
  },
  "lsd_2025_y77": {
    "id": 144,
    "name": "Lsd 2025 Y77",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 176.7,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US7901141",
    "safety_score": 84,
    "efficacy_score": 80,
    "drug_likeness": 81,
    "confidence_score": 81,
    "discovery_date": "2025-09-02T11:51:09.829008",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 75
    },
    "bioactivity_data": {
      "ic50_values": [
        13.708533382121194,
        621.3923151861698,
        509.4712257373079,
        901.1079226646768,
        16.3897377526981
      ],
      "ki_values": [
        373.7196886626149
      ],
      "ec50_values": [
        1574.621481410072
      ]
    },
    "research_notes": [
      "Compound lsd_2025_y77 shows promising activity in Research Phase applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2024.9948",
        "title": "Pharmacological characterization of lsd_2025_y77 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1038/nature.2024.8970",
        "title": "Pharmacological characterization of lsd_2025_y77 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1126/science.2024.7444",
        "title": "Pharmacological characterization of lsd_2025_y77 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 97
      },
      {
        "doi": "10.1038/nature.2020.8060",
        "title": "Pharmacological characterization of lsd_2025_y77 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 89
      },
      {
        "doi": "10.1124/jpet.2021.8974",
        "title": "Pharmacological characterization of lsd_2025_y77 and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829048"
  },
  "stim_2024_c78": {
    "id": 145,
    "name": "Stim 2024 C78",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 167.39,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US6942958",
    "safety_score": 77,
    "efficacy_score": 66,
    "drug_likeness": 94,
    "confidence_score": 82,
    "discovery_date": "2025-09-23T11:51:09.829058",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 51
    },
    "bioactivity_data": {
      "ic50_values": [
        259.54503810195723
      ],
      "ki_values": [
        473.7017791448767,
        46.47666839248121
      ],
      "ec50_values": [
        81.94468379457032
      ]
    },
    "research_notes": [
      "Compound stim_2024_c78 shows promising activity in Preclinical applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2024.7913",
        "title": "Pharmacological characterization of stim_2024_c78 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 85
      },
      {
        "doi": "10.1124/jpet.2023.7868",
        "title": "Pharmacological characterization of stim_2024_c78 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 97
      },
      {
        "doi": "10.1021/jmedchem.2024.5062",
        "title": "Pharmacological characterization of stim_2024_c78 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829087"
  },
  "opi_2025_y79": {
    "id": 146,
    "name": "Opi 2025 Y79",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 205.79,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US5700156",
    "safety_score": 80,
    "efficacy_score": 97,
    "drug_likeness": 89,
    "confidence_score": 76,
    "discovery_date": "2025-06-04T11:51:09.829093",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 86
    },
    "bioactivity_data": {
      "ic50_values": [
        853.5140494275549
      ],
      "ki_values": [
        371.9737393728924,
        390.5732970693797
      ],
      "ec50_values": [
        192.97527085429863,
        150.02654107659316,
        606.2657955233022,
        845.9517996678624
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2023.6870",
        "title": "Pharmacological characterization of opi_2025_y79 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 95
      },
      {
        "doi": "10.1016/j.neuropharm.2021.9571",
        "title": "Pharmacological characterization of opi_2025_y79 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 91
      },
      {
        "doi": "10.1124/jpet.2022.1491",
        "title": "Pharmacological characterization of opi_2025_y79 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1021/jmedchem.2024.5176",
        "title": "Pharmacological characterization of opi_2025_y79 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 86
      },
      {
        "doi": "10.1124/jpet.2021.7265",
        "title": "Pharmacological characterization of opi_2025_y79 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829130"
  },
  "ket_2025_x80": {
    "id": 147,
    "name": "Ket 2025 X80",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 151.69,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 62,
    "efficacy_score": 83,
    "drug_likeness": 86,
    "confidence_score": 74,
    "discovery_date": "2025-08-11T11:51:09.829134",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 72
    },
    "bioactivity_data": {
      "ic50_values": [
        645.3370750058752,
        165.22566470824086
      ],
      "ki_values": [
        35.69745764548512,
        283.906402375511,
        284.478232716564
      ],
      "ec50_values": [
        592.985224728063,
        635.7787921527649
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound ket_2025_x80 shows promising activity in Novel Therapy applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2021.2557",
        "title": "Pharmacological characterization of ket_2025_x80 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 92
      },
      {
        "doi": "10.1016/j.neuropharm.2022.4149",
        "title": "Pharmacological characterization of ket_2025_x80 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 92
      },
      {
        "doi": "10.1126/science.2024.5138",
        "title": "Pharmacological characterization of ket_2025_x80 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 89
      },
      {
        "doi": "10.1016/j.neuropharm.2024.8529",
        "title": "Pharmacological characterization of ket_2025_x80 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 96
      },
      {
        "doi": "10.1016/j.neuropharm.2022.4529",
        "title": "Pharmacological characterization of ket_2025_x80 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829195"
  },
  "anti_2024_c81": {
    "id": 148,
    "name": "Anti 2024 C81",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 443.3,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US4898156",
    "safety_score": 68,
    "efficacy_score": 98,
    "drug_likeness": 77,
    "confidence_score": 76,
    "discovery_date": "2024-10-30T11:51:09.829201",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 63
    },
    "bioactivity_data": {
      "ic50_values": [
        58.95911219816427,
        410.71846425543566,
        16.15360210052652,
        398.04653982316677,
        44.79425009581916
      ],
      "ki_values": [
        52.11891552241869
      ],
      "ec50_values": [
        1542.5620047096847,
        38.99508619309999,
        1962.570124720505
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2022.2856",
        "title": "Pharmacological characterization of anti_2024_c81 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1016/j.neuropharm.2021.1042",
        "title": "Pharmacological characterization of anti_2024_c81 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 97
      },
      {
        "doi": "10.1126/science.2022.9562",
        "title": "Pharmacological characterization of anti_2024_c81 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1016/j.neuropharm.2020.6172",
        "title": "Pharmacological characterization of anti_2024_c81 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 87
      },
      {
        "doi": "10.1124/jpet.2024.4804",
        "title": "Pharmacological characterization of anti_2024_c81 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829246"
  },
  "ket_2025_z82": {
    "id": 149,
    "name": "Ket 2025 Z82",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 170.32,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US4489625",
    "safety_score": 81,
    "efficacy_score": 71,
    "drug_likeness": 75,
    "confidence_score": 92,
    "discovery_date": "2025-02-07T11:51:09.829251",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 70
    },
    "bioactivity_data": {
      "ic50_values": [
        157.0695901329684,
        564.5687874597451
      ],
      "ki_values": [
        312.858369401571,
        474.4295458150475
      ],
      "ec50_values": [
        155.7927941999158
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2022.2000",
        "title": "Pharmacological characterization of ket_2025_z82 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 96
      },
      {
        "doi": "10.1038/nature.2020.5730",
        "title": "Pharmacological characterization of ket_2025_z82 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 92
      },
      {
        "doi": "10.1016/j.neuropharm.2023.9412",
        "title": "Pharmacological characterization of ket_2025_z82 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 96
      },
      {
        "doi": "10.1016/j.neuropharm.2021.8937",
        "title": "Pharmacological characterization of ket_2025_z82 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829291"
  },
  "mdma_2025_x83": {
    "id": 150,
    "name": "Mdma 2025 X83",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 397.37,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 64,
    "efficacy_score": 80,
    "drug_likeness": 89,
    "confidence_score": 73,
    "discovery_date": "2024-11-14T11:51:09.829296",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 55
    },
    "bioactivity_data": {
      "ic50_values": [
        529.1372155178384,
        970.988772365782,
        323.73180116576725,
        215.01381747859477
      ],
      "ki_values": [
        268.2729111139732
      ],
      "ec50_values": [
        1341.3627328275923,
        77.42782910838207
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound mdma_2025_x83 shows promising activity in Discovery Phase applications."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2022.5051",
        "title": "Pharmacological characterization of mdma_2025_x83 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829327"
  },
  "bzd_2024_b84": {
    "id": 151,
    "name": "Bzd 2024 B84",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 230.81,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US8685374",
    "safety_score": 66,
    "efficacy_score": 72,
    "drug_likeness": 62,
    "confidence_score": 80,
    "discovery_date": "2024-11-05T11:51:09.829335",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 59
    },
    "bioactivity_data": {
      "ic50_values": [
        203.12515665256007
      ],
      "ki_values": [
        126.34666477793213,
        336.9758337067648,
        275.15575556581604
      ],
      "ec50_values": [
        1536.2485201124593,
        1160.5634001404885,
        1180.0379877734472
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2021.1258",
        "title": "Pharmacological characterization of bzd_2024_b84 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 86
      },
      {
        "doi": "10.1126/science.2020.6957",
        "title": "Pharmacological characterization of bzd_2024_b84 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 88
      },
      {
        "doi": "10.1126/science.2021.2626",
        "title": "Pharmacological characterization of bzd_2024_b84 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829395"
  },
  "anti_2025_z85": {
    "id": 152,
    "name": "Anti 2025 Z85",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 336.37,
    "therapeutic_area": "Preclinical",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 76,
    "efficacy_score": 89,
    "drug_likeness": 94,
    "confidence_score": 71,
    "discovery_date": "2025-02-07T11:51:09.829401",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 69
    },
    "bioactivity_data": {
      "ic50_values": [
        781.8114438506154
      ],
      "ki_values": [
        260.81279820096773,
        34.872495119084675
      ],
      "ec50_values": [
        362.4130583317746,
        1304.4059586048445
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound anti_2025_z85 shows promising activity in Preclinical applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2021.8750",
        "title": "Pharmacological characterization of anti_2025_z85 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 85
      },
      {
        "doi": "10.1124/jpet.2021.9347",
        "title": "Pharmacological characterization of anti_2025_z85 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 86
      },
      {
        "doi": "10.1124/jpet.2022.3475",
        "title": "Pharmacological characterization of anti_2025_z85 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829432"
  },
  "lsd_2024_c86": {
    "id": 153,
    "name": "Lsd 2024 C86",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 271.84,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US7749985",
    "safety_score": 81,
    "efficacy_score": 80,
    "drug_likeness": 65,
    "confidence_score": 94,
    "discovery_date": "2025-01-25T11:51:09.829438",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 54
    },
    "bioactivity_data": {
      "ic50_values": [
        731.1317668594891,
        341.2012017193572,
        314.6884380170926,
        308.7611432473716,
        610.1002019614135
      ],
      "ki_values": [
        7.1512938718163,
        314.9769766676648,
        104.04126607118184
      ],
      "ec50_values": [
        736.6782356663023,
        1552.9566108848467,
        83.60326288659694,
        332.2676055281938
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound lsd_2024_c86 shows promising activity in Discovery Phase applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2020.8663",
        "title": "Pharmacological characterization of lsd_2024_c86 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1038/nature.2021.4329",
        "title": "Pharmacological characterization of lsd_2024_c86 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 88
      },
      {
        "doi": "10.1126/science.2020.2570",
        "title": "Pharmacological characterization of lsd_2024_c86 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829479"
  },
  "opi_2025_z87": {
    "id": 154,
    "name": "Opi 2025 Z87",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 332.48,
    "therapeutic_area": "Novel Therapy",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 66,
    "efficacy_score": 75,
    "drug_likeness": 55,
    "confidence_score": 92,
    "discovery_date": "2024-10-02T11:51:09.829484",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 52
    },
    "bioactivity_data": {
      "ic50_values": [
        247.0702466010998
      ],
      "ki_values": [
        13.823773268477764
      ],
      "ec50_values": [
        1294.9291193013355
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2021.1474",
        "title": "Pharmacological characterization of opi_2025_z87 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 86
      },
      {
        "doi": "10.1021/jmedchem.2021.5261",
        "title": "Pharmacological characterization of opi_2025_z87 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 88
      },
      {
        "doi": "10.1124/jpet.2023.1546",
        "title": "Pharmacological characterization of opi_2025_z87 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 98
      },
      {
        "doi": "10.1038/nature.2020.2525",
        "title": "Pharmacological characterization of opi_2025_z87 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829517"
  },
  "anti_2024_b88": {
    "id": 155,
    "name": "Anti 2024 B88",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 208.31,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US1824807",
    "safety_score": 92,
    "efficacy_score": 65,
    "drug_likeness": 89,
    "confidence_score": 83,
    "discovery_date": "2025-02-06T11:51:09.829525",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 90
    },
    "bioactivity_data": {
      "ic50_values": [
        423.4039034344052,
        704.5222187875777,
        296.83508010684557,
        722.0571596143623
      ],
      "ki_values": [
        482.04849868600644,
        80.58910701460255,
        359.00686562131096
      ],
      "ec50_values": [
        1394.0538308380794,
        9.882717749917893
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2022.3249",
        "title": "Pharmacological characterization of anti_2024_b88 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 94
      },
      {
        "doi": "10.1016/j.neuropharm.2020.3682",
        "title": "Pharmacological characterization of anti_2024_b88 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2020.2089",
        "title": "Pharmacological characterization of anti_2024_b88 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 91
      },
      {
        "doi": "10.1016/j.neuropharm.2024.3684",
        "title": "Pharmacological characterization of anti_2024_b88 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829558"
  },
  "anti_2025_x89": {
    "id": 156,
    "name": "Anti 2025 X89",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 490.63,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US1794343",
    "safety_score": 64,
    "efficacy_score": 84,
    "drug_likeness": 95,
    "confidence_score": 77,
    "discovery_date": "2024-12-13T11:51:09.829563",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 74
    },
    "bioactivity_data": {
      "ic50_values": [
        395.6839365781527,
        93.23183204527334,
        964.7796664787662
      ],
      "ki_values": [
        141.09231215574457,
        412.83699207928265,
        9.850614963539229
      ],
      "ec50_values": [
        1193.9171439879717
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.8592",
        "title": "Pharmacological characterization of anti_2025_x89 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 87
      },
      {
        "doi": "10.1124/jpet.2022.2337",
        "title": "Pharmacological characterization of anti_2025_x89 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 89
      },
      {
        "doi": "10.1126/science.2021.9307",
        "title": "Pharmacological characterization of anti_2025_x89 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829614"
  },
  "bzd_2024_b90": {
    "id": 157,
    "name": "Bzd 2024 B90",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 237.99,
    "therapeutic_area": "Research Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US3956397",
    "safety_score": 85,
    "efficacy_score": 74,
    "drug_likeness": 94,
    "confidence_score": 94,
    "discovery_date": "2025-03-15T11:51:09.829620",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 57
    },
    "bioactivity_data": {
      "ic50_values": [
        770.8836003695004,
        240.14875651247766,
        451.73689385612397
      ],
      "ki_values": [
        7.627231239677487,
        284.04197165359284,
        447.6810343100847
      ],
      "ec50_values": [
        1221.062156030933,
        1819.5531656858518,
        1164.5627598882984,
        221.2960409097376
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound bzd_2024_b90 shows promising activity in Research Phase applications."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2024.4659",
        "title": "Pharmacological characterization of bzd_2024_b90 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 89
      },
      {
        "doi": "10.1038/nature.2024.6674",
        "title": "Pharmacological characterization of bzd_2024_b90 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829655"
  },
  "stim_2024_b91": {
    "id": 158,
    "name": "Stim 2024 B91",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 401.22,
    "therapeutic_area": "Research Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US7464143",
    "safety_score": 89,
    "efficacy_score": 68,
    "drug_likeness": 63,
    "confidence_score": 93,
    "discovery_date": "2024-10-21T11:51:09.829660",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 51
    },
    "bioactivity_data": {
      "ic50_values": [
        528.8657784247367,
        425.0584445668595,
        474.3166879133049,
        354.8350566287179
      ],
      "ki_values": [
        1.5278620372401612
      ],
      "ec50_values": [
        981.5781881087472
      ]
    },
    "research_notes": [
      "Compound stim_2024_b91 shows promising activity in Research Phase applications.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2020.3712",
        "title": "Pharmacological characterization of stim_2024_b91 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 94
      },
      {
        "doi": "10.1124/jpet.2020.5078",
        "title": "Pharmacological characterization of stim_2024_b91 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 96
      },
      {
        "doi": "10.1124/jpet.2024.5146",
        "title": "Pharmacological characterization of stim_2024_b91 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1038/nature.2021.9621",
        "title": "Pharmacological characterization of stim_2024_b91 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829693"
  },
  "bzd_2025_y92": {
    "id": 159,
    "name": "Bzd 2025 Y92",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 170.35,
    "therapeutic_area": "Research Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US7373216",
    "safety_score": 95,
    "efficacy_score": 68,
    "drug_likeness": 86,
    "confidence_score": 79,
    "discovery_date": "2025-08-14T11:51:09.829698",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 63
    },
    "bioactivity_data": {
      "ic50_values": [
        490.47333609141873
      ],
      "ki_values": [
        470.2669569562752,
        491.7067150939156
      ],
      "ec50_values": [
        1094.5805191932232
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound bzd_2025_y92 shows promising activity in Research Phase applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2022.9025",
        "title": "Pharmacological characterization of bzd_2025_y92 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1016/j.neuropharm.2024.4296",
        "title": "Pharmacological characterization of bzd_2025_y92 and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 88
      },
      {
        "doi": "10.1126/science.2020.5508",
        "title": "Pharmacological characterization of bzd_2025_y92 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829730"
  },
  "opi_2025_z93": {
    "id": 160,
    "name": "Opi 2025 Z93",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 369.27,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US9415274",
    "safety_score": 65,
    "efficacy_score": 87,
    "drug_likeness": 92,
    "confidence_score": 77,
    "discovery_date": "2024-10-03T11:51:09.829736",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 71
    },
    "bioactivity_data": {
      "ic50_values": [
        604.0403605399202,
        871.8023368376215,
        879.1494992247488,
        677.4316148040571
      ],
      "ki_values": [
        411.13805713492053,
        458.9623983608448
      ],
      "ec50_values": [
        1057.9770377085097,
        903.9269725390224
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound opi_2025_z93 shows promising activity in Novel Therapy applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2021.5416",
        "title": "Pharmacological characterization of opi_2025_z93 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 95
      },
      {
        "doi": "10.1126/science.2022.7998",
        "title": "Pharmacological characterization of opi_2025_z93 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 94
      },
      {
        "doi": "10.1124/jpet.2021.2524",
        "title": "Pharmacological characterization of opi_2025_z93 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 89
      },
      {
        "doi": "10.1021/jmedchem.2022.5937",
        "title": "Pharmacological characterization of opi_2025_z93 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 97
      },
      {
        "doi": "10.1038/nature.2020.3215",
        "title": "Pharmacological characterization of opi_2025_z93 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829774"
  },
  "stim_2025_x94": {
    "id": 161,
    "name": "Stim 2025 X94",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 263.27,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US1979607",
    "safety_score": 90,
    "efficacy_score": 78,
    "drug_likeness": 66,
    "confidence_score": 97,
    "discovery_date": "2025-04-08T11:51:09.829780",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 86
    },
    "bioactivity_data": {
      "ic50_values": [
        998.8247864259039,
        766.9558811251043,
        21.377757885204883
      ],
      "ki_values": [
        164.04859094332656
      ],
      "ec50_values": [
        146.380056472512
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound stim_2025_x94 shows promising activity in Discovery Phase applications."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.4977",
        "title": "Pharmacological characterization of stim_2025_x94 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 97
      },
      {
        "doi": "10.1126/science.2023.7086",
        "title": "Pharmacological characterization of stim_2025_x94 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 93
      },
      {
        "doi": "10.1016/j.neuropharm.2022.4083",
        "title": "Pharmacological characterization of stim_2025_x94 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829820"
  },
  "ket_2025_y95": {
    "id": 162,
    "name": "Ket 2025 Y95",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 420.67,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US9230072",
    "safety_score": 68,
    "efficacy_score": 65,
    "drug_likeness": 66,
    "confidence_score": 94,
    "discovery_date": "2024-12-09T11:51:09.829830",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 72
    },
    "bioactivity_data": {
      "ic50_values": [
        857.368039622198,
        717.6694139661789,
        916.0335858390549
      ],
      "ki_values": [
        229.89405141273102,
        475.2001894669017,
        401.22635241967856
      ],
      "ec50_values": [
        1810.5831900890748,
        919.4749102917517
      ]
    },
    "research_notes": [
      "Compound ket_2025_y95 shows promising activity in Research Phase applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2022.6481",
        "title": "Pharmacological characterization of ket_2025_y95 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829861"
  },
  "mdma_2025_x96": {
    "id": 163,
    "name": "Mdma 2025 X96",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 297.88,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 89,
    "efficacy_score": 83,
    "drug_likeness": 84,
    "confidence_score": 73,
    "discovery_date": "2025-04-02T11:51:09.829866",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 67
    },
    "bioactivity_data": {
      "ic50_values": [
        914.5018052974795,
        757.5314006768665,
        412.5609974713674,
        949.107270518648,
        833.5657827544145
      ],
      "ki_values": [
        400.35344732329503,
        200.2197072178976
      ],
      "ec50_values": [
        1045.3853052555253,
        797.7235505506147
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound mdma_2025_x96 shows promising activity in Research Phase applications."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2023.6121",
        "title": "Pharmacological characterization of mdma_2025_x96 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2023.2752",
        "title": "Pharmacological characterization of mdma_2025_x96 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 93
      },
      {
        "doi": "10.1016/j.neuropharm.2023.1725",
        "title": "Pharmacological characterization of mdma_2025_x96 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 95
      },
      {
        "doi": "10.1124/jpet.2021.4029",
        "title": "Pharmacological characterization of mdma_2025_x96 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829899"
  },
  "mdma_2025_x97": {
    "id": 164,
    "name": "Mdma 2025 X97",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 350.93,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US5386388",
    "safety_score": 77,
    "efficacy_score": 79,
    "drug_likeness": 60,
    "confidence_score": 74,
    "discovery_date": "2025-03-13T11:51:09.829905",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 76
    },
    "bioactivity_data": {
      "ic50_values": [
        452.58985755300887,
        468.7877762581088,
        995.3081958338555,
        645.3653867523814
      ],
      "ki_values": [
        228.57878586224857,
        51.937165950887724
      ],
      "ec50_values": [
        894.2686443255982
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2021.6286",
        "title": "Pharmacological characterization of mdma_2025_x97 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 86
      },
      {
        "doi": "10.1016/j.neuropharm.2023.5403",
        "title": "Pharmacological characterization of mdma_2025_x97 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829934"
  },
  "bzd_2025_z98": {
    "id": 165,
    "name": "Bzd 2025 Z98",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 315.6,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 69,
    "efficacy_score": 98,
    "drug_likeness": 63,
    "confidence_score": 98,
    "discovery_date": "2024-11-18T11:51:09.829941",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 68
    },
    "bioactivity_data": {
      "ic50_values": [
        611.5632371465953,
        891.0649163886617
      ],
      "ki_values": [
        412.60063320119315,
        305.93807299213097,
        245.1537246428932
      ],
      "ec50_values": [
        1831.7536905633658,
        780.4241401276611
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound bzd_2025_z98 shows promising activity in Novel Therapy applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.3020",
        "title": "Pharmacological characterization of bzd_2025_z98 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 86
      },
      {
        "doi": "10.1126/science.2021.8512",
        "title": "Pharmacological characterization of bzd_2025_z98 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829968"
  },
  "ket_2024_b99": {
    "id": 166,
    "name": "Ket 2024 B99",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 202.47,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US6063035",
    "safety_score": 92,
    "efficacy_score": 90,
    "drug_likeness": 79,
    "confidence_score": 75,
    "discovery_date": "2025-07-18T11:51:09.829974",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 58
    },
    "bioactivity_data": {
      "ic50_values": [
        673.9340436315313
      ],
      "ki_values": [
        343.34168363365256,
        230.41359907522676,
        50.57226110906406
      ],
      "ec50_values": [
        1329.5457524359028,
        426.3729295079914
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.2276",
        "title": "Pharmacological characterization of ket_2024_b99 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T11:51:09.829998"
  }
}